

NATH & ASSOCIATES PLLC

Attorneys at Law

1030 Fifteenth Street, N.W.

Sixth Floor

Washington, D.C. 20005-1503

TELEPHONE (202) 775-8383

(202) 775-9393

FACSIMILE (202) 775-8396

(202) 822-9409

E-Mail: ip@nathlaw.com

Web: www.nathlaw.com

Gary M. Nath (DC, NJ)

Harold L. Novick (DC, MD)

Todd L. Juneau (DC, IL)

Irvin A. Lavine (DC), Retired*

Donald M. Sandler (MD), Retired*

*Patent, Trademark and Copyright Causes
Unfair Competition, Trade Secrets,
Licensing and Litigation*

**Practice limited to Matters and Proceedings
before Federal Courts and Agencies; not Admitted
in DC*

Michelle L. Hartland (VA)*

Lee C. Heiman (CA)*

Jerald L. Meyer (VA)*

Paul A. Sacher (MD)*

David R. Murphy (VA)*

Marvin C. Berkowitz (GA)*

Tanya E. Jankovic (MD)*

Joshua B. Goldberg (VA)*

Nahied K. Usman (VA)*

Alvin E. Tanenholtz **

Charles D. Niebylski, Ph.D.**

Deborah H. Yellin**

Roger C. Hahn**

** Registered Patent Agent: not Admitted in DC

FORM PTO-1082

TRANSMITTAL FOR NEW U.S. PATENT APPLICATION

Assistant Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Re: New U.S. Patent Application

For: **CRUDE EXTRACT FROM *Viscum album*
coloratum, AND PROTEINS AND LECTINS
ISOLATED THEREFROM**

Inventor(s):	Jongbae KIM	Jinhwan KWAK
	Seongkyu SONG	Byeoungdoo SONG
	Byungsun SUH	Taekjoon YOON
	Kwanee LEE	Taebong KANG
	Myoungsool DOO	Choonho PARK
Attorney Docket:	24107	

Sir:

Attached hereto is the application identified above, including:

- 109 Pages Application Consisting of:
- 76 Pages of Textual Specification
 - 7 Pages of 48 Claims
 - 1 Abstract of the Disclosure
 - 25 Sheets of drawings.
 - ☐ Executed Inventor's Declaration
 - ☒ Unexecuted Inventor's Declaration
 - ☐ Small Entity Statement
 - ☐ Assignment and cover sheet
 - ☐ Priority Document

The Government filing fee* is calculated as follows:

Total Claims	<u>48</u> - 20 = <u>28</u>	x \$18.00 =	<u>\$504.00</u>
Independent Claims	29. \div .3 = .26	.x. \$78.00 =	<u>\$2,028.00</u>
Base Fee			<u>\$690.00</u>
Multiple Dependent Claim Fee (\$260.00)			<u>\$ 0.00</u>
Subtotal			<u>\$3,222.00</u>

TOTAL FILING FEE*

(accounting for possible small entity status) \$3,222.00

— *Reduced by one-half, as applicant(s) is/are a "small entity".
A Declaration Claiming Small Entity Status:

— is submitted herewith;

— will be filed at a later date.

X Foreign priority is claimed under 35 U.S.C. § 119 from KOREA
Patent Application(s) No. 99-30638 dated July 27, 1999.

X Priority document(s) will be submitted at a later date.

— Priority document(s) is/are submitted herewith.

X Executed Declaration(s) will be submitted at a later date
pursuant to 37 CFR § 1.41 and § 1.53, with an appropriate
surcharge under 37 CFR § 1.16(e).

X Formal drawing(s) is/are attached.

— Formal drawing(s) will be submitted at a later date.

— Assignment document(s) is/are submitted herewith; the recorda-
tion fee of \$40.00 per document is enclosed herewith.

X Assignment document will be submitted at a later date.

— A Verified Translation will be submitted at a later date.

X No payment is enclosed at this time. Full payment will be
made when the executed Declaration is submitted.

— Submitted herewith is a check in the amount of \$_____.

Respectfully submitted,

NATH & ASSOCIATES PLLC



Gary M. Nath
Registration No. 26,965
Todd L. Juneau
Registration No. 40,669
Customer No. 20529

Date: July 27, 2000
NATH & ASSOCIATES PLLC
1030 15TH Street NW - 6th Floor
Washington, D.C. 20005
(202)-775-8383
GMN/TLJ/NKU/dd (1082)

002240 537 22960



07/27/00

BOX PATENT APPLICATION
Attorney Docket No. 24170

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jongbae KIM	Jinhwan KWAK
Seongkyu SONG	Byeoungdoo SONG
Byungsun SUH	Taekjoon YOON
Kwanee LEE	Taebong KANG
Myoungsool DOO	Choonho PARK

Serial No. NOT YET ASSIGNED

Filed: July 27, 2000

For: **CRUDE EXTRACT FROM *Viscum album coloratum*, AND PROTEINS AND LECTINS ISOLATED THEREFROM**TRANSMITTAL LETTERThe Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter
- (2) PTO Form-1082
- (3) 109 page Application consisting of:
 - 76 pages Textual Specification
 - 7 pages of 48 claims
 - 1 page containing the Abstract of the Disclosure
 - 25 sheets drawings
- (4) Unexecuted Declaration/Power of Attorney
- (5) Postcard for early notification of serial number.

Respectfully submitted,
NATH & ASSOCIATES PLLCBy: Gary M. Nath
Registration No. 26,965
Todd L. Juneau
Registration No. 40,669
Customer No. 20529Date: July 27, 2000
NATH & ASSOCIATES PLLC
1030th 15TH Street, NW - 6th Floor
Washington, D.C. 20005
GMN/TLJ/NKU/dd:APPL.transjc759 U.S. PTO
09/627165
07/27/00

002220" SAT 22960

i ;

**CRUDE EXTRACT FROM *Viscum album coloratum*, AND PROTEINS
AND LECTINS ISOLATED THEREFROM**

FIELD OF THE INVENTION

5

The present invention relates, in general, to a crude
extract from *Viscum album coloratum* and proteins and
lectins isolated therefrom. More particularly, the present
invention relates to an extract from *Viscum album*
10 *coloratum* which enhances biological immunity with
antitumoral activity and can be applied for an adjuvant to
induce cell-mediated immunity. Also, the present invention
is concerned with proteins and lectins which are present as
medicinally effective ingredients in the extract.

15

BACKGROUND OF THE INVENTION

Mistletoe, scientifically named *Viscum album*, is a
semi-parasitic plant that lives in or on various tree
20 hosts, from the body of which it obtains nutriment, and as
many as about 1,500 species thereof, which belong to about
30 genuses, are now known to be present over the world. Of
various mistletoes, the species belonging to the genus
Viscum, especially *Viscum album loranthacea* that inhabits
25 European areas, are used as medicinal materials. From a
long time ago, such European *loranthacea* mistletoe had been

used as a mysterious folk remedy curative of hypertension, arteriosclerosis, cancers, etc. In 1921, the *loranthacea* mistletoe was acknowledged to be of anticancer activity and, from then, has been used as a curative or a
5 therapeutical aid against tumors.

Accordingly, active research has been directed mainly to the biological activity of the European mistletoes, reporting that they have the immunity enhancement effect of stimulating humoral and cell-mediated immune systems as
10 well as activate macrophages and natural killer cells, both taking direct and indirect part in controlling tumor cells, to inhibit the growth of tumor cells and improve the viability of patients suffering from cancers. Also, mistletoe is found to exert cytotoxicity directly on tumor
15 cells. Representative of active materials of mistletoe are lectin components, which are divided into letin-I, -II and III according to sugar chain specificity and molecular weight. Immunological and biochemical attention is being paid largely to lectin-I.

20 Korean mistletoe (*Viscum album coloratum*), distinguishable from European mistletoe, has been used as medicinal materials effective for the treatment of lumbago, hypertension and toothache and the prevention of miscarriage in Korean folk remedies and Oriental herb
25 medicine. Particularly, in Oriental herb medicine, different names are given to mistletoes in accordance with

09627165-072700

the kinds of the host trees, suggesting that there might be differences in medicinal efficacy and effective component between the mistletoes which grow in or on different host trees. As a matter of fact, European mistletoes were reported to be different from one to another in lectin components in accordance with their host trees. Hence, the possibility cannot exclude that Korean mistletoes might be also different in components on account of their different host trees.

On the basis of such possibility, Khwaja et al. reported the anti-tumor effects and active components of Korean mistletoes for the first time in Korea, asserting that, unlike European mistletoes, the anti-tumor effects of Korean mistletoes come from the cytotoxicity attributable to alkaloids of strong toxicity rather than from lectins and thus, Korean mistletoes are quite different from European ones in active components against tumors and anti-tumor activity mechanism. However, no details for the difference have yet been reported.

Recent research of the present inventors has demonstrated that Korean mistletoes also directly activated macrophages to induce the secretion of interleukin-1 (hereinafter referred to as "IL-1") and tumor necrosis factor- α (hereinafter referred to as "TNF- α ") and that the activators to induce the secretion of these cytokines are proteinaceous ingredients which are precipitated by

09027165-072700

ammonium sulphate. In result, two kinds of lectins were isolated from Korean mistletoes.

5

SUMMARY OF THE INVENTION

Therefore, it is an object of the present invention to provide an extract from Korean mistletoe, which is of immunity enhancement and activity against tumor metastasis and can be used as an adjuvant material for vaccines applicable for the induction of cell-mediated immunity.

10

It is another object of the present invention to provide protein fractions and lectin fractions, which both are present as immunologically effective ingredients in the extract from Korean mistletoe.

15

It is a further object of the present invention to provide DNA base sequences coding for the lectins extracted from Korean mistletoe.

20

BRIEF DESCRIPTION OF THE INVENTION

Fig. 1 shows the isolation of the lectin fraction KML-C from the protein fraction KM-AS derived from the Korean mistletoe extract of the invention through a hydrolyzed sepharose-4B column in a chromatogram (A) and in an electrophoresis pattern (B).

25

Fig. 2 shows the cytotoxicity effects of KM-110 and KM-AS over B16-BL6 (A), Raji (B) and normal lymphocyte (C).

Fig. 3 shows the responses of the immuno-competent cell administered with KM-110 to mitogens Con. A and LPS.

5 Fig. 4 shows the response of the immuno-competent cell administered with KML-C to Con. A.

Fig. 5 shows the IL-1 induction by KM-110 (A and B) and KM-AS (C).

10 Fig. 6 shows the IL-1 induction activity by KML-C isolated from KM-AS.

Fig. 7 shows the IL-1 secretion into the culture supernatants of the macrophages stimulated with samples.

Fig. 8 shows the activity of KM-110, KML-C, EML-1 and C-free AS to secrete TNF- α , IL-C and IFN- γ .

15 Fig. 9 shows the fractions eluted with various concentrations NaCl to isolate an IFN- γ inducer from KML-C in a chromatogram.

Fig. 10 shows the IFN- γ induction activity of the fractions eluted with various concentrations of NaCl.

20 Fig. 11 shows NK-cell activity changes according to the administration period of time and concentration of KM-110.

Fig. 12 shows the NK cell activity induced KML-C against the cell proliferation of YAC-1.

25 Fig. 13 shows the activity of KM-110 against tumor metastasis in Balb/c mice and C57BL/6 which are injected

with KM-110 intravenously, subcutaneously, orally, and nasotracheally, two days before the transplantation of tumors.

Fig. 14 shows the activity of KML-C against the tumor metastasis of the lung cancer caused by colon 26-M3.1 cells.

Fig. 15 shows the killing activity of mouse macrophage induced by KM-110 over B16-BL6 melanoma.

Fig. 16 shows the effect of KM-110 on the metastasis of colon 26-M3.1 lung cancer in the mice deprived of NK-cells by the injection of anti-asialo-GM1 antibody.

Fig. 17 shows the inhibitory activity of KM-110 against tumor-dependent vascularization and tumor growth *in vivo*.

Fig. 18 shows the effects of KM-110 and KML-C on the antibody production of KLH.

Fig. 19 shows the sub-isotype analysis results of the KLH-specific antibodies induced by the immunization with KLH alone and in combination with KM-110.

Fig. 20 shows antigen-specific differentiation activity of the splenocytes immunized with KLH.

Fig. 21 shows the induction results of IL-2 and IL-4 from mouse splenocytes immunized with KLH.

Fig. 22 shows the increase in footpad tumor number in the mice immunized with combinations of KM-110, KML-C and KLH compared with in the mice immunized with KM-110, KML-C

and KLH alone.

Fig. 23 shows the increase induced by KM-110 in the CTL activity over xenogenic tumor cells.

Fig. 24 shows the specific differentiation of splenocytes upon tumor vaccine and KM-110 alone or in combination.

Fig. 25 shows the cross reaction of monoclonal antibodies 9H7-D10 and 8B11-2C5 with KML-C and EML-I.

Fig. 26 shows the separation of lectins KML-IIU and KML-IIL from KML-C by immuno-affinity chromatography.

Fig. 27 shows the cross reaction of monoclonal antibodies 9H7-D10 and 8B11-2C5 with KML-IIU, KML-IIL and EML-I.

Fig. 28 shows the neutralization effects of monoclonal 9H7-D10 and 8B11-2C5 on the cytotoxicity of each lectin.

Fig. 29 shows the comparison in cytokine induction activity of KML-II and KML-IIL with EML-I.

Fig. 30 shows the repressive activity of lectins on tumor metastasis, based on their cytotoxicity and cytokine induction activity.

Fig. 31 shows the comparison in the antibody production against HBV among KM-110, KML-IIU, and KML-IIL.

Fig. 32 is a schematic view showing a recombinant plasmid carrying a cloned lectin gene.

Fig. 33 shows the DNA base sequence and the amino acid sequence of KML-IIU.

Fig. 34 shows the DNA base sequence and the amino acid sequence of KML-IIL.

Fig. 35 shows the synergistic activity in anti-mycoplasma antibody production, induced by composite
5 adjuvants containing KM-110.

Fig. 36 are standard curves based on Sandwich ELISA for KML-C (A) and KML-IIU (B).

DETAILED DESCRIPTION OF THE INVENTION

10

One- or two-year-old Korean mistletoe is used as the substance of the present invention. Its leaves, stems and fruits are squashed in distilled water. The resulting solution is centrifuged and the supernatant is filtered by
15 use of a membrane. The filtrate is freeze-dried to give a brown powder, which is designated "KM-110" hereinafter.

From KM-110, a protein fraction is obtained by precipitation using ammonium sulphate. KM-110 is added in a 70% saturated ammonium sulphate solution and allowed to
20 precipitate by weakly stirring. The precipitate is purified by dialysis to give a protein fraction, called KM-AS.

Column chromatography is useful to further fractionate KM-AS. For this, a column is filled with sepharose-4B
25 which is previously hydrolyzed with 0.2 M HCl and then, KM-AS is let to pass through the column. As an eluent, a

002220"5972360

solution of 0.1M lactose in PBS is used to collect fractions. The resulting eluate is further purified by dialysis to give a lectin component, call KML-C. Its molecular weight can be determined by SDS-PAGE.

5 In addition to electrophoresis, another electrophoretic method frequently used for characterizing proteins is based on differences in their isoelectric points. This method, called isoelectric focusing, is adapted to determine whether the Korean mistletoe lectin component KML-C is different from or identical to the European mistleto lectin component EML-I. As a result of isoelectric focusing, KML-C was revealed to be quite different from EML-I at least in isoelectric point.

10 In order to investigate the immunological activity of KM-110 and KM-AS, they are applied to B16-BL6, Raji and mouse lymphocytes, which are then subjected to cytotoxicity assay.

15 The relation with the mitogens for immune-competent cells is helpful in understanding the entity of KM-110 and its purified fractions KM-AS and KML-C. For this, a mitogen such as Con. A or LPS is applied to the immune-competent cells taken from mice which are already injected with the sample of interest, that is, KM-110, KM-AS or KML-C. Using radioactive labels, the DNA synthesis in the immune-competent cells is examined. Compared with normal mice, the mice administered with KM-110, KM-AS or KML-C are

09627165-072700

improved in the activity of DNA synthesis within mature immunocytes, but not within immature cells.

002220 SAT 22860
In connection with the enhancement of host immune defense, it is also needed to reveal how KM-110, KM-AS and
5 KML-C function in the host. First, they are examined for cytokine induction. Macrophages are taken from the abdominal cells of mice and stimulated with the samples. After culturing, the culture media is examined for the secretion of IL-1 by ELISA. This examination is also
10 applied for other cytokines, such as TNF- α , IL-6 and IFN- γ . IL-1 is induced by all of the samples and, in particular, in a KML-C concentration-dependent pattern. Thus, KML-C is mainly responsible for the induction of IL-1. TNF- α and IL-6 is found to be induced by all of the samples. As for
15 IFN- γ , it can be induced by KM-AS, but not by KML-C. Accordingly, it is required to identify the factor that induces IFN- γ .

For the isolation of the IFN- γ inducer, a heparin column (Pharmacia) is employed. From C-free AS, which is
20 a fraction of KM-AS free of KML-C, a protein fraction is isolated through the heparin column. As a test, the activity to induce IFN- γ was detected largely from the fraction which was eluted by a phosphate buffer containing 100 mM NaCl. Thus, the ingredient of KM-110 which has the
25 activity of inducing IFN- γ is a Korean mistletoe heparin binding protein (KMHBPP) fraction.

Next, KM-110, KML-C and KMHBP are examined for their safety in the body. After being intravenously injected with the samples at various doses, mice are observed as to whether they die or can survive. The lethal dose LD₅₀ was
5 estimated to be 1.0-1.5 mg/mouse (about 1.25 mg/mouse) for KM-110, about 12.5 µg/mouse for KM-AS, 1.25 µg/mouse for KML-C, and 50-100 µg/kg of body weight for KMHBP.

Whether KML-C has a repressive activity against tumor Metastasis is also examined. Regarding colon 26-M3.1
10 carcinoma, more than 5 ng of KML-C can prevent the metastasis of the cancer. This antitumoral activity of KML-C is also effective to L5178Y-ML25 lymphoma. The antitumoral activity of KML-C is believed to result from the direct cytotoxicity effect on tumor cells as well as
15 the immunological stimulation to induce the activity of macrophages and NK-cells, which both are involved in the defense mechanism against tumors.

With regard to the enhancement of the host defense system, attention is turned to the tumor cell killing
20 activity of macrophage. Macrophages taken from the mice administered with KML-C are co-cultured with tumor cells, such as B16-BL6 melanoma, after which the killing activity of the macrophages is observed. The tumor cell killing activity of macrophages is known to be carried out by
25 secreting TNF-α or by bringing themselves into direct contact with tumor cells in addition to being related to

the secretion of killing materials, in the inventors' estimation.

Following are the separation of lectin components from KML-C, and the characterization thereof. In addition, a
5 description will be given of the genes coding for the lectin components.

To be used for the separation of lectin components later, anti-KML-C monoclonal antibodies are obtained by use of P3U1 myeloma. Through an antibody-specific ELISA
10 experiment, there are obtained three types of antibodies: 9H7-D10 highly specific for KML-C, 8B11-2C5 with high cross-reactivity for KML-C and EML-I, and 8E12-3E9 with a positive reaction against KML-C. As for antibody subtype, 9H7-D10 and 8B11-2C5 both proved to be of an IgG1 type
15 while 8E12-3E9 was of an IgM type.

By immuno-affinity column chromatography using these antibodies, two lectin components, respectively called "KML-IIU" and "KML-IIL", were obtained. They both are heterodimers consisting of two domains as analyzed by
20 electrophoresis. In detail, KML-IIU is 61.8 kD in molecular weight, consisting of a 33.2 kD peptide chain and a 28.6 kD peptide chain while KML-IIL has a molecular weight of 56.4 kD composed of a 31 kD peptide chain and a 28.6 kD peptide chain. KML-IIU and KML-IIL are both
25 restrained from hemagglutinating by lactose, galactose, and N-acetylgalactoseamine. On the other hand, the

09627165-072700

hemagglutination of EML-I is reported to be inhibited by lactose and galactose. Because none of Korean and European lectins are inhibited from hemagglutinating by glucose, a component composing lactose, the Korean mistletoe lectins separated according to the present invention are of specificity for galactose and N-acetylgalactosamine.

To compare the amino acid sequences of KML-IIU and KML-IIL with that of EML-I, N-terminal amino acid sequencing was conducted. As a result of the amino acid sequence analysis, KML-IIU is believed to have a different structure from European lectins EML-I, -II and -III in terms of at least the amino acid sequence from the N-terminal to the 30th amino acid residue in one polypeptide chain. Also, KML-IIL is revealed to be quite different from the European lectins in amino acid sequence in the other polypeptide chain.

These lectins of the present invention are also tested for their immunity enhancement through the experiments concerning cytotoxicity, cytokine induction, and activity against tumor metastasis as in the above. In these experiments, the lectins KML-IIU and KML-IIL both prove to be immunologically effective materials.

Of the antibodies prepared above, 9H7-D10 antibody shows specific reactivity for KML-IIU without a cross-reaction with KML-IIL and EML-I while 8B11-2C5 antibody reacts with all of KML-IIU, KML-IIL and EML-1. On the

00220"5972360

basis of this result, 9H7-D10 antibody can neutralize the cytotoxicity of KML-IIU only, whereas 8B11-2C5 antibody is of cytotoxicity neutralization activity over KML-II, KML-IIL and EML-I. Thus, KML-IIU and KML-IIL are different in at least epitope from EML-1. In addition, 8B11-2C5 antibody shows cross-reactivity to all Korean and European lectins. Thus, KML-IIU and EML-I may be identical to each other or have remarkably similar epitopes. However, KML-IIL is a lectin different from EML-I when considering that KML-IIL is different in sugar specificity and B-chain amino acid sequence from EML-I in addition to having 10-folds more potent cytotoxicity than does EML-I.

The immunity enhancement action of KML-IIU and KML-IIL can be identified by the antibody productivity against an antigen. In this regard, the pre-S2 domain of hepatitis B virus (HBV), which is of pathogenicity, is used. Each lectin adjuvant shows higher antibody titer than does the control, aluminum hydroxide adjuvant in the first week after injection. Each lectin can induce higher initial immune responses than the alum adjuvant. In the second week after booster injection, KM-110 and KML-IIU were similar in antibody titer to the alum adjuvant, but KML-IIL shows an antibody titer twice larger than those of the other samples. Similar to the aluminum-based adjuvant in the aspect of maintaining antibody production, the adjuvants of the invention can induce antigen-specific

002220"59722960

antibody production until the fifth week of the initial immunization.

In order to molecular-biologically approach the lectins of the invention, portions of Korean mistletoe lectin genes were cloned. Based on the amino acid sequences of purified KML-IIU and KML-IIL, a set of two oligopeptides were designed as primers:

Primer 1: 5'-GTIACICATCAIACIGG-3'

Primer 2: 5'-ACIATICGC ACIGTIGGTC-3'

From the genomic DNA of Korean mistletoe, a portion of the gene of interest was amplified by PCR. The clones obtained were base-sequenced. Some differences in base sequence among the clones suggest that there might exist various isoforms of Korean mistletoe. From the DNA base sequences, amino acid sequences can be deduced.

Using the extracts of the present invention, various adjuvants which show immunity enhancement activity can be prepared. For this, KM-110 is mixed with conventional adjuvants and the combined adjuvants are measured for the antibody titer against an antigen, such as mycoplasma. As a result, a significant immunological enhancement effect was obtained by adding KM-110 to conventional adjuvants, indicating that KM-110 can be used to prepare immunologically more effective adjuvants.

Next, the difference in the lectin content and thus, in the immunological effect of mistletoe extracts is

considered according to the various host trees. The protein contents in various extracts are different from one host tree to another. In the mistletoes tested, *Prunus*-parasitic mistletoe contains the most abundant KML-C. Thus, the highest cytotoxicity is obtained from the the *Prunus*-parasitic mistletoe extract which was highest in lectin content, as measured by a lectin assay.

Because the lectin fraction KML-C can induce cytokines such as TNF- α , IL-1 and IL-6 while KMHBP shows IFN- γ induction activity, a mixture (KM) of KML-C and KMHBP can effectively induce all of the cytokines tested, TNF- α , IL-1, IFN- γ and IL-6. In addition, this mixture KM is greatly decreased in direct cytotoxicity on normal cells. Consequently, KM is improved not only in cytokine induction activity, but also is safe to normal cells. In a test, the KM fraction, composed of KMHBP separated through a heparin column and KML-C, did not cause a sudden death in mice, so that the lethal material(s) is removed by the separation through the heparin column. KM is not different in the repressive activity against tumor metastasis from KM-110, so that it maintains the activity of KM-110 as it is.

A better understanding of the present invention may be obtained in light of the following examples which are set forth to illustrate, but are not to be construed to limit the present invention.

EXAMPLE 1: Extract of Korean Mistletoe and Protein Fraction
Isolated therefrom

Used were mistletoes that had been grown for one or
5 two years in Korea before being gathered in January. From
the plants were taken the leaves, stems and fruits within
the stretch from branch ends to the second knarls, and they
were sufficiently washed with distilled water, packed in
vacuo, and stored at -80 °C until the next use. After being
10 thawed, the mistletoe leaves and stems were finely cut,
mixed by use of a blender, and stirred at 4 °C for 8-12
hours in five volumes of distilled water. Then, the
solution was centrifuged at 10,000 rpm at 4 °C for 30 min
and the supernatant was let to pass through membranes which
15 were different in pore size (7.2, 0.45 and 0.22 μ m), in
order. Freeze-drying the filtrate afforded a brown powder,
KM-110. The yield of KM-110 from Korean mistletoe was 10%.

To make a stock solution, this freeze-dried powder was
dissolved at a concentration of 10 mg/ml in a phosphate
20 buffer (pH 7.4) (hereinafter referred to as "PBS"), and
aliquoted before storage at -20 °C. Isolation of protein
from the extract KM-110 was achieved in a precipitation
method using ammonium sulphate. Korean mistletoes were
stirred in a solution of 0.15 M NaCl of PBS in the same
25 manner as in the preparation of KM-110 and added with
ammonium sulphate powder to the extent of 70 % of the

saturation. Weakly stirring the 70% saturated ammonium sulphate solution at 4 °C allowed the precipitation of proteinaceous ingredients. After being dissolved in PBS, the precipitates were dialyzed against a buffer while the
5 buffer was changed to a fresh one every other day. The supernatant obtained from the centrifugation of the dialyzate at 15,000 g for 30 min was passed through a 0.45 μ m membrane filter to give a protein fraction, which was subjected to quantitative analysis with the aid of a
10 protein assay kit (Boehringer Mannheim) and called KM-AS. It was stored at -20 °C until the next use. The yield of KM-AS from mistletoe was 0.3 to 1.5 %.

EXAMPLE II: Isolation of Lectin Components and
15 Determination of their Molecular Weights

Isolation of lectin components from KM-AS was conducted through column chromatography using the sepharose-4B which was previously hydrolyzed with 0.2 M
20 HCl. KM-AS obtained in Example I was let to pass through the column which was then washed with five column volumes of PBS until the absorbance (O.D.) at 280 nm was zero. A solution of 0.1 M lactose in PBS was used as an eluent to separate the materials bound to the column and the eluate
25 was dialyzed against PBS to remove the lactose. The dialyzate was called KML-C.

To determine the molecular weight and purity of KML-C, the dialyzate was electrophoresed on a 13% polyacrylamide gel containing 0.1 % SDS, together with a protein marker (Fig. 1B).

5

EXAMPLE III: Reactivity to the Mitogens for Immune-Competent Cells

6-week-old Balb/c female mice, which were grouped in
10 threes, were injected with 100 μ g of KM-110 through an intravenous route and splenocytes were taken from each group after 1, 3 and 5 days of the injection.

The splenocytes were put in each well of flat-bottomed 96-well culture plates (Nunc, Denmark) at a density of 5×10^5
15 cells/100 μ l, after which the cells in each well were treated with 100 ml of Con. A and LPS, known as mitogens of T cells and B cells respectively, at a density of 0.5 and 5 μ g/ml, respectively. Cell culturing was conducted at 37 °C for 3 days in a 5% CO₂ atmosphere. At 6 hours before the
20 completion of the cell culturing, [³H]-TdR of 0.5 μ Ci was added to the cells in each well, followed by adsorbing the cells to glass filters with the aid of Filter Mate 196 (Packard Instrument, Meriden CT), which were subsequently measured for radioactivity in Matrix 96TM Direct Beta
25 Counter (Packard).

The results are given in Fig. 3. As seen in the

figure, the administration of KM-110 led to direct stimulation to the cells (lymphocytes) responsible to the immunity in various organs. Compared with the lymphocytes of normal mice, the lymph nodes (LN), peripheral lymphocytes (PL), spleen lymphocytes (SL) of the KM-110 administered mice were improved in DNA synthesis when being cultured after the treatment with Con. A and LPS, which are mitogens of T and B cells respectively. That is, KM-110 showed an effective response to the mitogens. This response began to increase after the first day of the KM-110 administration and at least doubled on the third day after the administration, compared with that of the normal mice, and had a tendency to decline on the fifth day. Since no effective responses were found from bone marrow cells, a kind of immature cells, KM-110 is believed to exert its action only on mature immunocytes.

100 μ g of KM-110 was measured to contain 1.5 μ g of proteins. In order to examine the activity of the protein fraction alone among the components of KM-110, an equal amount of KM-AS was administered into mice. As apparent from the results, the splenocytes of the mice administered with each of the samples were more increased in DNA synthesis, even when not stimulated by the mitogens, compared with the non-administered control. This demonstrates that the sample materials stimulate the cell proliferation of splenocytes *in vivo*. In addition, when

used together with the mitogens, the samples of interest were found to amplify the activity of the mitogens. As for KML-C, its administration resulted in increasing the activity of the mitogen in proportion to its concentration, as seen in Fig. 4. Thus, there is a strong suggestion that, of the KM-110, the ingredient that stimulates immunity-related cells is KML-C, a lectin separated from the protein fraction KM-AS.

Taken together, the results obtained in this example demonstrate that KM-110 and its fractions enhance a series of cellular reactions to make mature immunocytes of hosts effectively perform the immune reactions as well as amplify the number of the cells involved in the antigen-specific immune reactions, which are induced when the hosts are exposed to antigens, thereby eliciting effective immunity against the antigens.

EXAMPLE 4: Cytokine Induction of KM-110, KM-AS and KML-C

Balb/c mice were peritoneally injected with 1 ml of 1% thioglycollate and euthanized by the separation of cervical vertebra after 4 days of the injection. 10 ml of an RPMI 1640 medium was injected to the peritoneal cavity of the dead mice whose abdominal walls were, then, lightly hit to mix well the abdominal cells. After being collected from the mice, peritoneal exudative cells were allotted at a

density of 1.5×10^6 cells per well in 24-well culture plates. After a 2 hour culturing, KM-110 and KM-AS were added at various concentrations in the wells and allowed to stimulate the macrophages attached on the plates for 24 hours. Following the stimulation, the induction of cytokines was examined. In this regard, first, a bioassay was conducted to determine whether the supernatants of the cell cultures were of IL-1 activity. Its confirmation was achieved with the aid of an ELISA kit (ENDOGEN). The results are given in Fig. 5. Based on the results, other cytokines, such as TNF- α , IL-6 and IFN- γ were measured for their induction activity by ELISA. The results are given as shown in Fig. 8.

COMPARATIVE EXAMPLE I: IL-1 Induction

After being stimulated with the samples of interest at 100 μ g-1 μ g/ml for 1 hour, macrophages were cultured in fresh media for 24 hours. As shown in Fig. 5a, the macrophage culture supernatant stimulated with KM-110 was comparable in IL-1 activity to that stimulated with LPS. Based on this result, an examination was made of the IL-1 activity change according to time periods at various concentrations of KM-110. As seen in Fig. 5b, IL-1 activities obtained at the concentration range of 100-10 μ g/ml were maximized to almost the same level at 10 hours

002220" SAT 23950

after the stimulation while the highest IL-activity was
obtained at 50 $\mu\text{g/ml}$ in an early stage of the stimulation
(until 5 hours after the stimulation). Meanwhile, whereas
no noticeable IL-1 activity was found at 500 $\mu\text{g/ml}$ even
5 after 24 hours of stimulation, the stimulation with 1 $\mu\text{g/ml}$
was recognized to elicit IL-1 activity after 24 hours.
From the above results, it is understood that the most
effective dose of IL-1 for the induction of IL-1 falls in
the range of 10-100 $\mu\text{g/ml}$ and the IL-1 activity of the
10 supernatant can be maintained at as low as 1 $\mu\text{g/ml}$.

To determine which component of KM-110 plays a
critical role in the induction of IL-1, KM-AS, the protein
component of KM-110, was tested. The protein component KM-
AS was used at an amount of 0.25 mg/ml in this experiment.
15 For use, it was diluted in a 100-fold dilution manner. As
shown in Fig. 5c, an activity of IL-1 induction was
obtained in KM-AS, indicating that the protein component of
KM-110 acts as an IL-1 inducer.

KML-C, isolated from KM-AS, was also investigated for
20 the activity for IL-1 induction and the result is given in
Fig. 6. The IL-1 induction in macrophage was noticeable in
the concentration range of KML-C from 50 ng/ml to 1 ng/ml,
exhibiting a KML-C concentration-dependent behavior.

By a bioassay, it was verified that the supernatant of
25 the macrophage cell culture stimulated with the mistletoe
components has IL-1 activity which activates T thymocytes

and KML-C is mainly responsible for the induction of IL-1. The confirmation of the secretion of IL-1 was achieved by ELISA. For ELISA assay of IL-1, samples of interest were used at the concentrations used to induce IL-1 activity in the bioassay (KM-110: 10 μ g/ml, KML-C: 10ng/ml). As a control, EML-I, which is a European mistletoe lectin, was used (10 ng/ml). As shown in Fig. 7, all of the test samples succeeded in inducing IL-1 from macrophages while KML-C was identified as one of the most important activators in the IL-1 induction of KM-110. Compared with EML-I, KML-C was believed to be a more active cytokine inducer for its higher IL-1 induction capability. The concentration at which for KML-C to induce macrophages to secrete IL-1 was estimated to range from 1 to 100 ng for mice and from 100 ng to 100 μ g for humans.

COMPARATIVE EXAMPLE 2: Induction of TNF- α , IFN- γ and IL-6

Using macrophage culture supernatant, KM-AS, KML-C, EML-I and C-free AS, which is a protein fraction free of KML-C, were tested for the induction of TNF- α , IFN- γ and IL-6. The results are given in Fig. 8. The fraction concentration capable of stimulating macrophages to induce the cytokines was found to be 5 μ l/ml for KM-AS and C-free AS and 10 μ l/ml for KML-C and EML-I. As seen, KM-AS, KML-C and C-free AS were able to induce IL-6 and TNF- α from

macrophages with superiority of KML-C to EML-I in the induction activity. IFN- γ was not induced by KML-C. On the other hand, C-free AS was as active to induce IFN- γ as KM-AS. From this result, it was deduced that the induction

5 IFN- γ from macrophages was carried out not by KML-C, a lectin component, but by another protein component. In addition, the activity of KM-110 to stimulate macrophages to induce IL-1, IL-6, TNF- α and IFN- γ was attributed generally to its protein fraction, KM-AS. Further, KML-C

10 was responsible for the induction of IL-1, IL-6 and TNF- α , but did not act as an inducer for IFN- γ . Accordingly, there was a requirement for the identification of the factor that induces IFN- γ . This work was carried out in the following Example 5.

15

EXAMPLE 5: Examination of IFN- γ Inducer in KM-AS

KML-C, a lectin fraction, was able to induce most of the cytokines induced by KM-110 or KM-AS, but could not

20 function as an INF- γ inducer, as mentioned in Example 4. As a material used to search for the IFN- γ inducer, C-free AS, which is a KM-AS fraction free of KML-C, was selected because it showed a useful activity of inducing IFN- γ . For the isolation of the IFN- γ inducer, a heparin column

25 (Pharmacia) was employed. After being dissolved in a phosphate buffer (0.01 M, pH 7.4), C-free AS was loaded on

00220"5972950

the heparin column which was, then, washed sufficiently with the same buffer until materials unbound to the column were throughly removed. After washing, the materials bound to the column were eluted by using an NaCl gradient (10 mM-
5 1 M) in the same buffer. Fig. 9 is a chromatogram showing the fraction patterns which were eluted depending on NaCl concentration. Because the elutates, even though not separated as being pure, showed different electrophoresis patterns, they were different from one another in terms of
10 at least the affinity for heparin.

Next, an examination was made to determine whether the eluted fractions were active to induce IFN- γ . Each of the fractions separated by the heparin column was used at concentrations of 200-5,000 ng/ml to stimulate macrophages and the resulting culture supernatants were investigated in
15 the same manner as in Comparative Example 2. The results are given in Fig. 10. As seen, the activity to induce IFN- γ was detected largely from the fraction which was eluted by a phosphate buffer containing 100 mM NaCl. Thus, the ingredient of KM-110 which had the activity of inducing
20 IFN- γ was a Korean mistletoe haparin binding protein (KMHBP) fraction which was eluted with 100 mM NaCl. In order to induce the most effective immune activity, therefore, there are required not only the lectin component
25 KML-C, but also the KMHBP ingredient (hereinafter referred to as "KMHBP-100") which is separated from C-free AS by

heparin column chromatography eluting with a 100 mM NaCl phosphate buffer. In mice, a mixture of 5-100 ng of KML-C and 100 ng-10 μ g of KMHBP-100 was functional to induce effective immune activity. When applied for humans, a mixture of 500 ng-100 μ g of KML-C and 10 μ g-10 mg of KMHBP-100 is effective.

EXAMPLE 6: *in vivo* Acute Toxicity of KM-110 and Other Fractions

KM-110, KML-C and KMHBP, which are extracts from mistletoe parasitic on *Quercus*, were examined for the acute toxic effects on mice. Into 6-week-old Balb/c mice (female), KML-C was intravenously injected at amounts of 5, 2.5, 1.25, and 0.62 μ g and KMHBP-100 at amounts of 110, 50 and 25 μ g. Afterwards, the mice were measured for body weight change and viability for 7 days. Each test group consisted of 10 mice.

The results are given in Tables 1 and 2, below. As seen in Table 1, when administered with KM-110, the 1.5 mg/mice group were all killed within 24 hours of the administration. On the other hand, no dead were found in the 1.0 mg/mice group. The mice which had been alive after being administered with 1.0 mg of KM-110, were decreased in body weight on the third day of the administration, but revived to the normal state on the fifth day. After 7 days

of administration, no outward abnormalities could be found from the mice group. The lethal dose LD_{50} , which stands for acute toxicity, was estimated to be 1.0-1.5 mg/mouse (about 1.25 mg/mouse) for KM-110 and about 12.5 μ g/mouse for KM-AS.

As for KML-C, a dose of 5 or 2.5 μ g per mouse made the mice undergo serious piloerection and adynamia and they were finally put to death within 2 days. In the 1.25 μ g/mice group, none were dead on the day of administration, but 2 mice were dead on the second day and another mouse on the third day. The mice administered with an amount of 1.25 μ g were decreased in body weight by about 5 % after 3-5 days of the administration as seen in Table 2, showing the piloerection and adynamia which were, to the inventor's knowledge, attributed to fever. From the sixth day of the administration, however, they were revived into the normal state, gaining in weight. No abnormalities were found in the 0.625 μ g/mice group, compared with normal mice. Thus, KML-C was estimated to have an LD_{50} of about 1.25 μ g.

In the 100 μ g/mice group administered with KMHBP-100, all were dead after one day of administration. Weight loss or other abnormalities could not be found in the group into which KMHBP-100 was injected at a dose of 50 μ g. Thus, the LD_{50} OF KMHBP-100 was estimated to be between 100 and 50 μ g/kg of body weight.

TABLE 1

Viability of Mice Administered with Mistletoe Extracts

Samples	Dose/ mouse	Days/Viability (%)							Results (%)
		1	2	3	4	5	6	7	
KM-110	1.5mg	0	-	-	-	-	-	-	0
	1.0mg	100	100	100	100	100	100	100	100
MKL-C	5 μ g	40	0	-	-	-	-	-	0
	2.5 μ g	80	0	-	-	-	-	-	0
	1.25 μ g	100	60	60	60	40	40	40	40
	0.625 μ g	100	100	100	100	100	100	100	100
KMHBP	100 μ g	0	0	0	0	0	0	0	0
	50 μ g	80	70	70	70	70	70	70	70
	25 μ g	100	100	100	100	100	100	100	100

TABLE 2

Weight Change According to i.v. Injection of Mistletoe Extracts

Samples	Dose/ Mouse	Days/Avg. Wt (g) \pm SD			
		1	3	5	7
	-	20.2 \pm 0.5	20.3 \pm 0.6	20.3 \pm 0.7	20.2 \pm 0.6
KM-110	1.5mg	-	-	-	-
	1.0mg	20.2 \pm 0.8	19.8 \pm 0.6	20.0 \pm 0.8	20.1 \pm 0.9
MKL-C	5 μ g	19.5 \pm 0.7	-	-	-
	2.5 μ g	19.4 \pm 0.5	-	-	-
	1.25 μ g	19.6 \pm 0.4	19.0 \pm 0.6	19.1 \pm 0.7	19.4 \pm 0.5

	0.625 μ g	20.2 \pm 0.5	19.7 \pm 0.6	20.0 \pm 0.6	20.1 \pm 0.6
KMHBP	100 μ g	-	-	-	-
	50 μ g	20.2 \pm 0.7	20.2 \pm 0.7	20.3 \pm 0.9	20.4 \pm 0.8
	25 μ g	20.2 \pm 0.7	20.5 \pm 0.8	20.6 \pm 0.8	20.6 \pm 0.9

EXAMPLE 7: Repressive Activity of KML-C Against Tumor Metastasis

5

Based on the result of the *in vitro* experiments concerning cytotoxicity and cytokine induction, in which KML-C was found to be one of the most important active ingredients of KM-110, an examination was made to determine which ingredient of KM-110 has inhibitory activity against tumor metastasis.

As shown in Fig. 14 which contains the experimental result regarding the preventive effects of the mistletoe extracts on colon 26-M3.1 carcinoma metastasis, the administration of 100 μ g of KM-110 resulted in the repression of tumor metastasis by more than 80 %. A similar repressive effect on tumor metastasis was detected between KM-AS and KM-110, indicating that the antitumoral activity of KM-110 exists in its protein ingredients. Like 100 μ g of KM-110, 50 ng of KML-C also showed the activity of repressing the tumor metastasis by more than 80 %. Since no repression effects on tumor metastasis were found from the administration of KML-C at a dose of 5 ng, the effective amount of KML-C for *in vivo* antitumoral activity

was measured to be over 5 ng.

The repressive effects on tumor metastasis of KM-110 and KML-C were also true of the L5178Y-ML25 lymphoma. With regard to tumor metastasis, the active ingredient of KM-110 was, thus, KML-C. As shown in Tables 3 and 4, the effective amount of KML-C to repress tumor metastasis in vivo was measured to range from 10 to 50 ng. The antitumoral activity of KML-C is believed to result from the direct cytotoxicity effect on tumor cells as well as the immunological stimulation to induce the activity of macrophages and NK-cells, which both are involved in the defense mechanism against tumors.

TABLE 3

Curing Effects of KML-C on the Metastasis of Tumors
Generated in Liver, Spleen and Lung
(Experiment I: L5178Y-ML25 Lymphoma cells)

Korean Mistletoe Treatment			Avg. Wt.(g)±SD(%)	
	Inoculating Time	Dose	Liver	Spleen
Normal Mice			1.07 ±0.1	0.09 ±0.02
Non-treated	(Tumor Control)		3.54 ±0.48	0.21 ±0.05
KM-110	1 day after tumor inoculation	100μg	0.59±0.22 (56.5)	0.14±0.02 (33.3) *
KML-C		50μg	1.83±0.84 (48.3) **	0.16 ±0.04

* p<0.05; **P<0.01, by student's two-tailed test, compared

TABLE 4

Curing Effects of KML-C on the Metastasis of Tumors
Generated in Liver, Spleen and Lung
(Experiment II: Colon 26-M3.1 Carcinoma cells)

Korean Mistletoe Treatment			No. of Lung Cancer Metastasis	
	Inoculating Time	Dose	Avg. Wt.±SD	Range
Non-treated	Tumor Control		100±13	85~17
KM-110	1, 2 and 3 days after tumor inoculation	100µg	62±30 (38.0)*	27~93
KM-AS		1.5µg	59±18 (41.0)**	44~83
KML-C		500ng	74±23 (26.0)	41~97
KML-C		25ng	54±27 (46.0)	26~77
KML-C		10ng	61±14 (39.0)	43~76
KML-C		1ng	98±11	82~108

* p<0.05; **P<0.01, by student's two-tailed test, compared

EXAMPLE 8: Tumor Cell Killing Activity by Activation of Macrophage

Macrophages, which take the lead in the immune surveillance system of the body, are well known as a defense tool against tumors, virus-infected cells, microbes, etc. With regard to antitumoral activity, macrophages kill tumor cells in two patterns: first, they secrete various cytokines which involve the immune mechanism of tumor cells; and they are brought into direct contact with tumor cells to exert their cytotoxicity effect on the tumor cells. In addition, macrophages induce a post-immune defense mechanism against the tumor cells.

To investigate whether the antitumoral activity of KM-110 and KML-C is related to the direct killing activity of macrophages, the materials of interest were injected into mice. 100 μ g of KM-110 or 50 ng of KML-C was used for the peritoneal injection into mice (B16-BL/c). After 2 and 4 days of receiving the injection, macrophages (effector cells) were disinfectively collected with the aid of RPMI-1640 media and measured for tumor cell killing activity. As a target tumor cell, B16-BL6 melanoma was labeled with radioactive isotope ^{51}Cr , and then added in 96-well culture plates at a cell density of 1×10^4 per well. To the wells in which the melanoma cells resided, the macrophages obtained from the mice administered with KM-110 or KML-C were added at cell densities of 1×10^5 and 5×10^4 per well, after which they both were co-cultured for 12 hours. As a control, macrophages obtained from the non-treated normal mice were utilized. After culturing, the activation of macrophages by the samples of interest was measured in tumor cell killing activity, which was calculated as follows:

$$\text{Killing Activity}(\%) = \frac{\text{experimental release} - \text{spontaneous release}}{\text{maximal release} - \text{spontaneous release}}$$

As shown in Fig. 15A, the macrophages of the mice injected with 100 μ g of KM-110 were about three times as high in the inhibitory activity against B16-BL6 melanoma cell proliferation as those of the mice which were not treated with KM-110. This inhibitory activity reached a maximal point on the second day of the KM-110 injection and began to decrease from the forth day. Thus, KM-110 is deemed to function to activate macrophages in vivo, leading to killing tumor cells. Based on this result, the tumor cell killing activity of macrophage according to KML-C injection was measured on the second day of the injection. As seen in Fig. 15B, the macrophages showed an improved activity of effectively killing ^{51}Cr -labeled B16-BL6 melanoma cells after 2 days of KML-C injection. These data obtained demonstrate that, of the KM-110 components, KML-C plays a major role in stimulating macrophages to exert the killing mechanism on tumor cells. The tumor cell killing activity of macrophages are known to be carried out by secreting $\text{TNF-}\alpha$ or by bringing themselves into direct contact with tumor cells. In addition, since activated macrophages secrete tumor cell-killing reactive oxygen (ROIs) and nitrogen monooxide (NO), the tumor cell killing activity of macrophages induced by KM-110 or KML-C would be related to the secretion of such killing materials, in the inventors' estimation.

EXAMPLE 9: Production and Characterization of Anti-KML-C
Monoclonal Antibody

For the production of anti-KML-C monoclonal antibody,
5 first, a PBS buffer containing KML-C at a concentration of
300 ng/100 μ l was emulsified with an equal volume of the
complete Freund's adjuvant and peritoneally injected into
Balb/c mice. After 14 days, the primarily immunized mice
were further immunized with the same amount of the antigen
10 emulsified with incomplete Freund's adjuvant. After 10 days
of the final immunization, a small amount of blood was
taken from the immunized mice and measured for the antibody
titer by an indirect ELISA in which the antigen was
immobilized. Subsequently, using the antigen (100 ng)
15 only, a booster injection was administered into the
abdominal cavity of the mice. After one week, the
splenocytes from the KML-C-immunized Balb/c mice were
subjected to the cell fusion to P3U1 myeloma with the aid
of PEG, followed by selecting the hybridoma cells in HAT
20 media. An ELISA was carried out to screen the hybridoma
cells which produced anti-KML-C antibodies. The hybridoma
cells were cloned in 96-well plates in such a manner that
one hybridoma existed in each well, and cultured to form
colonies. The culture supernatant of the hybridomas grown
25 to colonies was examined by ELISA to screen the hybridomas
which produces antibodies against KML-C. This cloning and

screening was repeated twice further to select the hybridoma cells which produce anti-KML-C monoclonal antibodies.

5 A large quantity of the monoclonal antibodies were required for their characterization. For this, the hybridoma cells were injected into the abdominal cavity of pristane-treated mice to obtain an ascitic fluid. The ascitic fluid was loaded on a protein-G affinity column to purify the monoclonal antibodies. Of them, the antibodies
10 which were of specific activity for KML-C alone and the antibodies which showed cross-reactivity for KML-C and EML-I were selected by ELISA. To this end, KML-C or EML-I was first coated at 2 μ g/ml on each well of an ELISA plate and blocked by BSA. Then, the ascitic fluid of hybridoma which
15 showed a positive reaction was added to the wells and allowed to stand for the antigen-antibody reaction. An HRP-conjugated secondary antibody was added to the wells, followed by coloring by use of TMB (Sigma) as a substrate. Absorbance at 450 nm was measured and the result is given
20 in Fig. 25. Through an antibody-specific ELISA experiment, 9H7-D10 was identified as an antibody highly specific for KML-C while 8B11-2C5 showed high cross-reactivity for KML-C and EML-I both, as seen in Fig. 25. As a result of a cross-reaction ELISA experiment, when the antibody titer of
25 each antibody was expressed as the dilution of the ascitic fluid which showed an optical density (O.D.) significantly

higher than that of NSB (non-specific binding) antibody, that is, an O.D of 0.5 or more, 9H7-D10 and 8B11-2C5 antibodies showed high antibody titers of more than 50,000 and 100,000, respectively. Additionally, 8E12-3E9 was also an antibody that showed a positive reaction against KML-C. As for antibody subtype, 9H7-D10 and 8B11-2C5 both proved to be of an IgG1 type while 8E12-3E9 was of an IgM type. These three antibodies were used for the isolation and fractionation of lectin, later.

10

EXAMPLE 10: Preparation of Immuno-Affinity Column and Isolation of KML-IIU and KML-IIL

15

9H7-D10, which was found to react specifically to KML-C without cross-reaction with EML-I as measured by an ELISA, was used to rapidly separate two lectin ingredients from KML-C by affinity chromatography. For this, the monoclonal antibody was immobilized in a HiTrip NHS activated affinity column (Pharmacia Boitech) according to the manufacturer's indication, so as to obtain an immuno-affinity column. The column was equilibrated with PBS (pH 7.4) and KML-C was allowed to pass through the column. Subsequently, the effluent fractions were obtained by flowing PBS and a glycine-HCl buffer (pH 2.7) through the column at an elution rate of 1 ml/2 min. Each effluete was measured for purity and molecular weight by 10% SDS-

20

25

polyacrylamide electrophoresis using KML-C and EML-I as controls. As shown in the results of Fig. 26, two fractions were separated from KML-C through the 9H7-D10 antibody-immobilized immuno-affinity column. The fraction which was larger in molecular weight according to the electrophoretic pattern, was called "KML-IIU" and the other "KML-IIL". Each of these fractions was found to be a heterodimer consisting of two domains which were different in molecular weight and linked to each other via a disulfide bond as analyzed by the electrophoresis on a mecaptoethanol-containing gel. In detail, KML-IIU was 61.8 kD in molecular weight, consisting of a 33.2 kD peptide chain and a 28.6 kD peptide chain while KML-IIL has a molecular weight of 56.4 kD composed of a 31 kD peptide chain and a 28.6 kD peptide chain. These constituent proteins are quite different in molecular weight from those of the European mistletoe lectin components (ML-I, -II, and -III) reported.

EXAMPLE 11: Sugar Specificity of KML-IIU and KML-IIL

To investigate whether the two protein fractions isolated from KML-C have lectin activity and for which sugar the two protein fractions, if being of lectin activity, exhibit specificity, experiments for hemagglutination and hemagglutination inhibition of sugar

00220"5972950

were carried out on U-type 96-well plates. A solution of 2% B-blood cell in PBS was added to each well of the plates, followed by the addition of various concentrations of the protein fractions to each well. After culturing for 1 hour at room temperature, the minimal concentrations at which the protein fractions can exhibit the hemagglutination were obtained (Table 5). As seen in Table 5, Korean mistletoe-derived KML-C and its KML-IIU and KML-IIL each hemagglutinated at a concentration of as low as 8 μ g/ml, so they were identified as lentin materials.

In order to examine the specificity of the lectin materials for sugars, various sugars were stepwise diluted from 100 mM and added to the protein fractions which were present at a concentration necessary to exhibit hemagglutination, thereby causing the inhibition of hemagglutination (Table 6). KML-C, KML-IIU and KML-IIL were all restrained from hemagglutinating by lactose, galactose, and N-acetylgalactoseamine. On the other hand, the hemagglutination of EML-I was inhibited by lactose and galactose as reported. Because none of Korean and European lectins were inhibited from hemagglutinating by glucose, a component composing lactose, the Korean mistletoe lectins separated according to the present invention were found to be of specificity for galactose and N-acetylgalatoseamine.

TABLE 5

Hemagglutination Activity of KMLIIU and KML-IIL

Lectin	Minimal Conc. ($\mu\text{g/mL}$)
KML-C	8
KML-IIU	8
KML-IIL	8
EML-1	2

TABLE 6

Minimal Concentrations of Various Sugars Necessary to Inhibit the Hemagglutination of KML-IIU and KML-IIL

Saccharides	Minimal Conc. (mM)
Galactose	6
Lactose	3
N-Acetylgalactosamine	3
Mannose	>100
Glucose	>100
N-Acetylglucosamine	>100

EXAMPLE 12: Amino Acid Sequences of KML-IIU, KML-IIL and European Lectins

N-terminal amino acid sequencing was conducted to

compare the amino acid sequences of KML-IIU and KML-IIL with that of EML-I. A- and B-chain of KML-IIU, separated from each other on a reduced SDS-PAGE, were transferred into a PVDF (polyvinylidene difluoride) membrane by electroblotting at 85 mA for 70 min. The protein bands blotted were hydrolyzed at 110 °C for 24 hours in 6M HCl and applied to an amino acid analyzer (Effendorf/Niotronic, LC 3000) to analyze the amino acid sequence of each chain. In this manner, the amino acid sequence of KML-IIL was revealed, and compared with that of the European lectin EML-I as shown in Table 7, below. Each chain was called A-chain when it appeared at a lower position on an electrophoresis because of its smaller molecular weight. On the other hand, the chain which appeared at an upper position owing to larger molecular weight was designated B-chain. As a result of the amino acid sequence analysis for the A-chain of KML-IIU, in an amino acid stretch from the N-terminal to the 30th amino acid residue, 24 amino acid residues, except for the 5th, the 15th, the 16th, the 27th, and the 28th amino acid residue, were found to be identical to those of the EML-I, so that the KML-IIU A-chain is 15% different from the EML-I A-chain. EML-I, -II, and -III are reported to be identical in the amino acid sequence from the N-terminal to the 30th amino acid residue. In addition, EML-II and -III are slightly smaller in molecular weight than EML-I and they are also distinguished even by

different sugar-specific isoforms. When these situations are taken into account, the A-chain of KML-IIU is believed to have a different structure from corresponding chains of the whole European lectins EML-I, -II and -III in terms of at least the amino acid sequence from the N-terminal to the 30th amino acid residue. Also, as a result of the analysis of B-chains, although the KML-IIU was unable to compare with the European lectins, KML-IIL was revealed to be quite different from the European lectins in amino acid sequence.

TABLE 7

Amino Acid Sequences of KML-IIU, KML-IIL and EML-I Chains

Lectin	Chain(Mw.)	Amino Acid Sequence			
		1	10	20	30
KML-IIU	A(30KDa)	YEREK	LRVTH QTTGD	QYFKF	ITLLA DQHS
KML-IIL	A(27.5KDa)	YEREK	LRVTH QTTGD	EYFRF	ITLLA DTV
EML-I	A(29KDa)	YEREK	LRVTH QTTGD	EYFRF	ITLLA DTVSS
		1	10	20	30
KML-IIU	B(32.5KDa)	unidentified			
KML-IIL	B(31KDa)	DVTXT ASEPT VRI			
EML-I	B(34KDa)	DDVTS SASEP TVRIV GRNGM			

EXAMPLE 13: Cytotoxicity Effects of KML-IIU and KML-IIL on Cancer Cells

An examination was made of in vitro cytotoxicity effects of Korean mistletoe lectins on various cell lines with a control of European mistletoe lectin (EML-1). First, a predetermined amount of each cell strain was added to 96-well plates and allowed to react with various concentrations of lectins. After 48 hours, the cell growth was measured by an XTT(?ATT) assay. In Table 8 are given the doses (ED_{50}) at which the samples of interest effectively inhibited the growth of each cell strain by 50%. Most of the lectins are comparatively highly resistant to B16-BL6 melanoma, Meth A fibrosarcoma cell lines while being relatively highly susceptible to 3LL carcinoma and Raji lymphoma, so that they are specific for some cancer cells. Over most cell lines, the cytotoxicity effects of KML-C were measured to be more potent than those of European lectins. In some cancer cell lines, the Korean mistletoe showed cytotoxicity 10 times as large as those of European lectins. Compared with KML-IIU, KML-IIL exhibited relatively higher cytotoxicity over all of colon 26-M3.1 carcinoma, B16-BL6 melanoma and L1210 leukemia cell lines.

TABLE 8

Killing Effects of Korean and European Mistletoe Lectins

Cell lines	Sources	Conc. to Inhibit Tumor Cell Growth by 50% (ED ₅₀) (/mL)			
		KML-C	KML-III U	KML-III L	EML-1
26-M3.1	Carcinoma	5ng	40ng	1.1ng	8.1ng
B16-BL6	Melanoma	15ng	140ng	21ng	320ng
L1210	Leukemia	1.5ng	20.1ng	1.5ng	1.5ng
Jurkat	Leukemia	110pg	2.0ng	90pg	2.0ng
HL60	Leukemia	-	50.5ng	1.0ng	21.0ng
Meth A	Fibrocarcinoma	-	210ng	-	1200ng
3LL	Carcinoma	-	80ng	-	30ng

EXAMPLE 14: Reactivity of Monoclonal Antibody to Each Lectin and Neutralization Effect of Cytotoxicity

Of the prepared monoclonal antibodies, 9H7-D10 and 8B11-2C5, which exhibited high reactivity to KML-C and EML-I, were used to examine the cross-reaction between monoclonal antibodies and lectins by a sandwich ELISA. 8E12-3E9 antibody, which is of an IgM type and cross-reacts with each lectin, was coated on each well of ELISA plates and allowed to react with various concentrations of each of KML-IIIU, KML-IIIL and EML-I. Thereafter, by taking advantage of a periodate method, an HRP conjugate was added to the 9H7-D10 and 8B11-2C5 to examine the reactivity between lectins and monoclonal antibodies. The result is given in Fig. 27. Without a cross-reaction with KML-IIIL

and EML-I, 9H7-D10 antibody showed specific reactivity for KML-IIU. On the other hand, 8B11-2C5 antibody reacted with all of KML-IIU, KML-IIL and EML-1.

On the basis of this result, an examination was made of the neutralization effect of the monoclonal antibodies on the cytotoxicity of the lectins (Fig. 28). As seen in Fig. 28, 9H7-D10 antibody could neutralize the cytotoxicity of KML-IIU only, whereas 8B11-2C5 antibody showed cytotoxicity neutralization activity over KML-II, KML-IIL and EML-I. As apparent from the data of Fig. 28, KML-IIU and KML-IIL are different in at least epitope from EML-1.

8B11-2C5 antibody was of cross-reactivity to all Korean and European lectins. Thus, KML-IIU and EML-I may be identical to each other or have remarkably similar epitopes. However, KML-IIL is a lectin probably different from EML-I when account is taken of the following aspects: KML-IIL is different in sugar specificity and B-chain amino acid sequence from EML-I in addition to having 10-folds more potent cytotoxicity than does EML-I.

20

EXAMPLE 15: Induction of Cytokines from Macrophage by KML-IIU and KML-IIL

The cytokine induction activity of KML-IIU and KML-IIL, both isolated from KML-C, was compared with that of EML-I by the same ELISA as in Example 4. When stimulating

macrophages, each lectin was used at a concentration of 50 ng/ml. The result is given in Fig. 29. KML-IIU and KML-IIL directly stimulated mouse macrophages to induce IL-1, IL-6 and TNF- α , but were lacking in the induction of IFN- γ . Slightly different as they were from each other depending on cytokines, KML-IIU and KML-IIL were both superior to EML-I in cytokine induction activity. Consequently, an activity difference as well as a biochemical difference resides between Korean and European mistletoes.

10

EXAMPLE 16: Repressive Effect of KML-IIU and KML-IIL on Tumor Metastasis

Based on the cytotoxicity and cytokine induction activity, the two lectins were examined for in vivo repressive activity against tumor metastasis. Selected as a tumor cell line used for this experiment was colon 26-M3.1 lung carcinoma and before a couple of days of tumor inoculation, mice were administered with the samples of interest by i.v. injection. Each lectin was used at doses from 1 to 100 ng per mouse. The result is given in Fig. 30. KML-IIU and EML-I showed similar activity against tumor metastasis when being administered at doses of 50-100 ng. KML-IIL was active at a dose 10-folds lower than that of KML-IIU and EML-I and thus, the suitable dose at which KML-IIL can exert antitumoral activity in mice ranges from

5 to 50 ng. Thus, KML-IIL was interpreted to be 10-folds more potent in in vivo antitumoral activity than KML-IIU.

EXAMPLE 17: Anti-HBV Antibody Productivity of KML-IIU and
5 KML-IIL

Comparison was made of immunological enhancement among KM-110, KML-IIU and KML-IIL. Used as an antigen was the pre-S2 domain of hepatitis B virus (HBV), which is of pathogenicity. Mice, which were grouped in fives, were immunized with the antigen by s.c. injection at two week intervals twice in total and, to fifteen weeks, sera were taken from the immunized mice to examine antibody titers. As a control, a 20% aluminum hydroxide adjuvant was employed. With regard to the ELISA to determine the antibody titer, the antigen was coated at an amount of 5 μ g/ml on each well of ELISA plates and allowed to react with various concentrations of anti-sera. To quantitatively measure antigen-antibody complexes, an HRP-conjugated secondary anti-mouse antibody (rabbit-anti-mouse-IgG+A+M-HRP; X8000, Zymed) was used. As a substrate for the enzyme reaction, TMB (Sigma) was added to the wells, followed by measuring absorbance at 450 nm (O.D.). The antibody titers were expressed as serum dilution ratios at which the O.D. of interest was three times as large as that of normal mice.

10
15
20
25

As shown in Fig. 31, KM-110 or each lectin adjuvant showed higher antibody titer than did the control, aluminum hydroxide adjuvant, in the first week after the initial immunization. Although aluminum-based adjuvants are generally known to show rapid responses, KM-110 and each lectin induced higher initial immune responses than the aluminum-based adjuvant. In the second week after the booster injection, KM-110 and KML-IIU were similar in antibody titer to the aluminum-based adjuvant, but KML-IIL showed an antibody titer twice larger than those of the other samples. Similar to the aluminum-based adjuvant in the aspect of maintaining antibody production, the adjuvants of the invention could induce antigen-specific antibody production until the fifth week of the initial immunization. As in the activity against tumor metastasis, the activity of the adjuvants, which have influence on the antibody productivity, turned out to be better in KML-IIL than in KML-IIU.

EXAMPLE 18: Partial Cloning of Korean Mistletoe Lectin Gene

Based on the amino acid sequences of purified KML-IIU and KML-IIL, two oligonucleotide primers were designed:

Primer 1: 5'-GTIACICATCAIACIGG-3'

Primer 2: 5'-ACIATICGC ACIGTIGGTC-3'

These primers were used to amplify a portion of the gene of

interest by PCR with the genomic DNA of Korean mistletoe serving as a template. In this regard, a PCR reaction comprising 1 μ g of the genomic DNA isolated by a CTAB method, 100 pmol of each primer, 200 μ l of each dNTP, 1.5 mM MgCl_2 , and 2.5 units of a DNA polymerase (Amplitaq, Perkin-Elmer) was subjected to 35 cycles of PCR, each consisting of a denaturing step at 94 °C for 1 min, an annealing step at 45 °C for 2 min and an extending step at 72 °C for 2 min, in a thermal cycler (Perkin-Elmer 9600). The PCR product, about 800 bp in length, was ligated into pGEM-T (Promega) at an *EcoRV* cloning site. The recombinant plasmid thus obtained was shown in Fig. 32.

EXAMPLE 19: Partial Base Sequence of Korean Mistletoe Lectin Gene and Its Amino Acid Sequence

Of the clones obtained, two were sequenced with the aid of an automated sequencer to determine their DNA base sequences as shown in Fig. 33 for a KML-IIU gene and in Fig. 34 for a KML-IIL gene. In general, plant lectins are reported to exist as various isoforms. Also, there are some differences in base sequence among the clones, suggesting that there might exist various isoforms of Korean mistletoe.

From the DNA base sequences, amino acid sequences were deduced (Figs. 33 and 34), and are listed in Tables 9a to

9d, below, along with other plant lectins' for comparison. In Tables 9a to 9d, "IIU" stands for the amino acid sequence of purified KML-IIU, "IIL" for the amino acid sequence of purified KML-IIU", "C1" for the amino acid sequence deduced from the DNA base sequence of PCR product clone 1, "C2" for the amino acid sequence deduced from the DNA base sequence of PCR product clone 2, "EMLA" for the amino acid sequence of European mistletoe lectin I A-chain, "EMLB" for the amino acid sequence of European mistletoe lectin I B-chain, "RTA" for the amino acid sequence of ricin toxin B-chain, "ABA" for the amino acid sequence of abrin A-chain, and "ABB" for the amino acid of abrin B-chain.

TABLE 9a

Amino Acid Sequence Comparison of Korean Mistletoe Lectins, European Mistletoe Lectins, and Other Related Lectins

<A Chain>																			
II U			Y	E	R	L	K	L	Y	-	V	T	H						
II L			Y	E	R	L	R	L	R	-	V	T	H	Q	T	T	G	D	E
GI												H	Q	T	T	G	D	E	Y
EMLA			Y	E	R	L	R	L	R	-	V	T	H	Q	T	T	G	E	E
RTA	I	F	P	K	Q	Y	P	I	I	N	F	T	T	A	G	A	T	V	Q
ABA			E	D	R	P	I	-	K	F	S	T	E	G	A	T	S	Q	S
II U																			
II L	Y	V																	
CI	Y	V	S	S	G	S	F	S	N		E	I	P	L	L	R	Q	S	T

5

10

15

EMLA	Y	V	S	S	G	S	P	S	N		E	I	P	L	L	R	Q	S	T	I	P	V	S	D	A	Q	R	F	V	L
RTA	R	L	T	T	G	A	D	V	R	H	E	I	P	V	L	P	N	R	V	G	L	P	-	I	N	Q	R	F	I	L
ABA	R	L	R	G	G	L	-	-	I	H	D	I	P	V	L	P	D	P	T	T	L	Q	-	E	R	L	R	Y	I	T
CI	V	E	L	T	N	Q	G	G	D	-	S	I	T	A	A	I	D	V	T	N	L	Y	V	V	A	Y	Q	A	G	D
EMLA	V	E	L	T	N	Q	G	Q	D	-	S	V	T	T	A	I	D	V	T	N	A	Y	V	V	A	Y	Q	A	G	D
RTA	V	E	L	S	N	H	A	-	E	L	S	V	T	L	A	L	D	V	T	N	A	Y	V	V	G	Y	R	A	G	N
ANA	V	E	L	S	N	S	D	T	E	-	S	I	E	V	G	I	D	V	T	N	A	Y	V	V	A	Y	R	A	G	T
CI	Q	S	Y	F	L	R	-	D	A	P	D	G	A	E	-	-	R	H	L	F	T	G	T	T	R	-	-	-	-	-
EMLA	Q	S	Y	F	L	R	-	D	A	P	R	G	A	E	-	-	T	H	L	F	T	G	T	T	R	-	-	-	-	-
RTA	S	A	Y	F	F	H	P	D	N	Q	E	D	A	E	A	I	T	H	L	F	T	-	-	-	-	D	V	Q	N	R
ABA	Q	S	Y	F	L	R		D	A	P	S	S	A	S	D	Y	-	-	L	F	T	G	T	-	-	D	-	Q	H	-
CI	S	S	L	P	F	T	G	S	Y	T	D	-	L	E	R	Y	A	G	H	-	-	R	D	Q	I	P	L	G	-	-
EMLA	S	S	L	P	F	N	G	S	Y	P	D	-	L	E	R	Y	A	G	H	-	-	R	D	Q	I	P	L	G	-	-
RTA	Y	F	T	A	F	G	G	N	Y	-	D	R	L	E	Q	L	A	G	-	N	L	R	E	N	I	E	L	G	N	G
ABA	-	S	L	P	F	Y	G	T	Y	G	D	-	L	E	R	W	A	-	H	Q	S	R	Q	Q	I	P	L	G	L	D

TABLE 9b

20

Amino Acid Sequence Comparison of Korean Mistletoe
Lectins, European Mistletoe Lectins, and Other Related
Lectins

25

30

<A chain>																															
C1	-	I	E	E	L	I	Q	S	V	S	A	L	-	-	I	Y	P	G	G	-	-	-	S	T	R	A	Q	A	R	S	
EMLA	-	I	D	Q	L	I	Q	S	V	T	A	L	-	-	I	F	P	G	G	-	-	-	S	T	R	T	Q	A	R	S	
RTA	P	L	E	E	A	I	-	-	-	S	A	L	Y	Y	Y	S	Y	G	G	T	Q	L	P	T	L	-	-	A	R	S	
ABA	A	L	T	H	G	T	-	-	-	S	F	F	-	-	R	S	-	G	G	N	D	N	E	E	K	-	-	A	R	T	
C2											A	R	F	N	P	I	X	W	R	L	R	R	Q	-	I	N	S	G	E	S	
C1	L	I	I	L	I	Q	M	I	S	E	A	A	R	F	N	P	I	F	W	R	-	A	R	Q	Y	I	N	S	G	E	S
EMLA	I	L	I	L	I	Q	M	I	S	E	A	A	R	F	N	P	I	L	W	R	-	Y	R	Q	Y	I	N	S	G	A	S

; ;

5

10

15

RTA	F	I	I	C	I	Q	M	I	S	E	A	A	R	F	Q	Y	I	E	G	E	-	M	R	T	R	I	R	Y	N	R	R
ABA	L	I	V	I	I	Q	M	V	A	E	A	A	R	F	R	Y	I	S	N	R	-	V	R	V	S	I	Q	T	G	T	A
C2	S	S	P	P	N	Y	M	L	E	L	E	T	S	W	G	R	Q	S	T	Q	V	Q	Q	S	K	-	D	G	I	F	
C1	F	L	P	D	M	Y	M	L	E	L	E	T	S	W	G	Q	Q	S	T	Q	V	Q	Q	S	T	-	D	G	V	F	
EMLA	F	L	P	D	V	Y	M	L	E	L	E	T	S	W	G	Q	Q	S	T	Q	V	Q	H	S	T	-	D	G	V	F	
RTA	S	A	P	D	P	S	V	I	T	L	E	N	S	W	G	R	L	S	T	A	I	Q	E	S	N	Q	G	A	-	F	
ABA	F	Q	P	D	A	A	M	I	S	L	E	N	M	W	D	N	L	S	R	G	V	Q	E	S	V	Q	D	T	-	F	
C2	N	T	Q	I	R	L	-	Q	I	S	A	G	M	F	-	V	-	T	S	X	N	V	R	D	V	-	I	-	-	S	
C1	N	N	P	F	R	L	-	G	I	S	T	G	M	F	-	V	-	T	L	S	N	V	R	D	V	-	I	-	-	A	
EMLA	N	N	P	I	R	L	-	A	I	P	P	G	M	F	-	V	-	T	L	T	N	V	R	D	V	-	I	-	-	A	
RTA	-	-	-	-	-	A	S	P	I	Q	L	Q	R	R	-	N	G	S	K	F	S	V	Y	D	V	S	I	L	I	P	
ABA	P	N	Q	V	T	L	T	N	I	R	N	E	P	V	I	V	D	S	L	S	H	P	T	-	V	-	-	-	-	A	
C2	S	L	A	I	M	L	F	E	C	S	G	R	P	F	S	S															
C1	S	L	A	I	M	L	F	V	C	R	D	R	P	S	S	S															
EMLA	S	L	A	I	M	L	F	V	C	G	E	R	P	S	S	S															
RTA	I	I	A	L	M	V	Y	R	C	A	P	P	P	S	S	Q	F														
ABA	V	L	A	L	M	L	F	V	C	N	P	P	P	P	N																

TABLE 9C

20

Amino Acid Sequence Comparison of Korean Mistletoe
Lectins, European Mistletoe Lectins, and Other Related
Lectins

25

30

<Linker>																													
C2			L	D	H	P	S	P	L	L	L	R	S	V	V	D	A	A	N										
C1			D	V	R	Y	W	P	L	V	I	R	P	V	L	E	N	S	G	A	V								
EMLA																													
RTA							S	-	L	L	I	R	P	V	V	P	N	F	N										
ABA			A	N	Q	S	P	L	L	I	R	S																	

TABLE 9d

002220 " 59T 22350

Amino Acid Sequence Comparison of Korean Mistletoe
Lectins, European Mistletoe Lectins, and Other Related
Lectins

5		<B chain>																			
	IIL		D	V	T	C	T	A	S	E	C	T	V	R	I						
	C2		D	V	T	X	T	X	S	E	P	T	V	R	I	V					
	CI	D	D	V	T	C	T	A	S	E	P	T	V	R	I	V					
	EMLB	D	D	V	T	S	S	A	S	E	P	T	V	R	I	V	G	R	N	G	M
10	RTB	A	D	V	C	M	D	P	-	E	P	I	V	R	I	V	G	R	N	G	M
	ABB	S	K	I	C	S	S	R	Y	E	P	T	V	R	I	G	G	R	D	G	M

EXAMPLE 20: Immunological Enhancement Effect of Complex
Adjuvant Containing Mistletoe

15 In this experiment, immunologically effective, novel
adjuvant formulations were prepared by combining KM-110
with conventional adjuvants. If a synergistic activity is
induced in the combinations by KM-110, various adjuvants
20 can be developed by use of KM-110. Since adjuvants should
be generally active against a broad spectrum of antigens,
mycoplasma, which is one of the pathogenic bacteria causing
pneumonia in domestic animals, was utilized in this
experiment. The antibody titer was measured in the same
25 manner as in Example 9 and the result is shown in Fig. 35.
As conventional adjuvants, 20% aluminum hydroxide and 3%
oil ASA25 were employed. As a result of the experiment, a
combination of 100 μ g of KM-110 and an alum adjuvant was

002220"59T2350

recognized to be active for the enhancement of antibody production, showing a similar effect to that obtained in Example 9. In contrast, a combination of KM-110 and the oil was poor in antibody productivity, compared with the combination of KM-110 and alum adjuvant. A couple of weeks after the booster injection with antigen, a combination of alum adjuvant and ASA25 induced about 5-folds greater antibody titer than did each of the adjuvants. That is, when the conventional adjuvants were combined, a better synergistic effect was induced than when the conventional adjuvants were used singly. When KM-110 was additionally combined with the combination of alum adjuvant and ASA25, the resulting adjuvant made the antibodies produced at an antibody titer about 10 times as large as that obtained when the conventional adjuvants were used singly. Therefore, a significant immunological enhancement effect was obtained by adding KM-110 to conventional adjuvants, indicating that KM-110 can be used to prepare immunologically more effective adjuvants.

20

EXAMPLE 21: Lectin Contents in Extracts from Mistletoes Parasitic on Different Hosts

As revealed above, the antitumoral activity or the immunological enhancement effect of KM-110 is dependent mainly on its lectin fractions. Because lectin plays a

role as an index material indicating the activity of the crude extract KM-110, development of a method for measuring the content of lectin has an important significance. In this example, an immuno assay method (sandwich ELISA) by which contents of KML-C and KML-IIU can be measured was developed by taking advantage of 9H7-D10, which is a monoclonal antibody specific for KML-IIU, and 8B11-2C5, which is of cross-reactivity with KML-IIU and KML-IIL. To this end, HRP was first conjugated to 9H7-D10 and 8B11-2C5 antibodies by a Lamini method with the aim of measuring the content of each lectin. As a coating Ab for a sandwich ELISA, 8E12-3E9 (x1,000), which is of an IgM type, was employed. After the antibodies were blocked by BSA, each lectin was diluted in series and allowed to react with the antibodies. After completion of the reaction, HRP-conjugated 9H7-D10 and 8B11-2C5 antibodies was reacted to their corresponding lectins. Addition of a TMB buffer induced a coloring reaction. Standard curves for KML-C and KML-IIU, which were drawn by use of sandwich ELISA, made KML-C and KML-IIU known to be detected in the range of 30 ng-2.5 μ g/ml and 80 ng-5 μ g/ml, respectively, as shown in Fig. 36. When applied to the standard curves of Fig. 6, the lectin contents of the mistletoes parasitic on 6 host trees were measured as shown in Table 10, below.

TABLE 10

: ;

Lectin and Total Protein Contents in Mistletoe Extracts
According to Host Trees

	Host Trees	Leaves	Protein(μ g)	KML-C(μ g)	KML-IIU(μ g)
5	Quercus	200mg	1864	64.8 \pm 8.6	33.8 \pm 2.5
	Catanea	200mg	1471	459.7 \pm 22.4	235.4 \pm 12.5
	Chaenomeles	200mg	1755	112.9 \pm 10.7	55.8 \pm 5.5
	Prunus	200mg	1258	710.2 \pm 31.7	429.7 \pm 36.5
	Ailanthus	200mg	935	88.8 \pm 8.2	47.2 \pm 3.8
10	Pyrus	200mg	748	94.5 \pm 7.3	52.9 \pm 5.2

The protein contents were different from one host tree to another, as shown in Table 10. The total protein content in 200 mg of each mistletoe was widely changed in accordance with host trees, ranging from 748 μ g to as much as 1864 μ g, which can be calculated as being from 0.374 to 0.923 weight by percentage. As measured by ELISA, KML-C amounted to 3.6 % in the total protein amount of *Quercus*-parasitic mistletoe and to 50 % in the total protein amount of *Prunus*-parasitic mistletoe: the latter is 21 times as great as the former. In the case of *Castanea*, the content of KML-C in the total protein was measured to be as much as 30 %. Based on the weight of the total protein, the parasitic mistletoe contained KML-C at an amount of 5.6 % in case of *Chaenomeles* host, at an amount of 8.2 % in case of *Ailanthus* host, and at an amount of 12.7 % in case of

Pyrus host. As for the percentage of KML-IIU in KML-C, it was calculated to be 53.7 ± 3.9 % on average, in the six host trees. Since the anticancer activity induced by the immune action of mistletoe has been revealed to be due mainly to the KML-C, thus far, the immunological enhancement of Korean mistletoe extracts is believed to be quite different from one host tree to another. The activity KMHBP and other active materials also might be different depending on hosts.

10

EXAMPLE 22: *in vitro* Cytotoxicity Effects of Extracts of Mistletoes Parasitic on Different Hosts

15

A measurement was made of the *in vitro* cytotoxicity effect that the extracts from mistletoes parasitic on different hosts exerted on various tumor cells. The *in vitro* anticancer activity of each mistletoe extract was expressed as the concentration (IC_{50}) at which each extract effectively inhibited the growth of each cell strain by 50 %.

As seen in Table 11, mistletoe extracts inhibited the growth of tumor cells at different activities according to the cell lines. In addition, the inhibitory activity was dependent on the hosts, showing a proportional relation to the lectin content in each mistletoe extract. The inhibitory activity against YAC-1 cell for example, was determined at IC_{50} of 200 ng/ml for *Quercus*, 30 ng/ml for

20

25

Castanea, 150 ng/ml for *Chaenomeles*, 5.6 ng/ml *Prunus*, 90 ng/ml for *Ailanthus*, and 60 ng/ml for *Pyrus*. The highest cytotoxicity was obtained from the extract from the *Prunus*-parasitic mistletoe extract which was highest in lectin content as measured by a lectin assay.

The immunological enhancement effect of the extracts from the mistletoes parasitic on different hosts was also found to come mainly from the lectin component KML-C.

TABLE 11
Killing Effect on Various Tumor Cell Lines Induced by
Mistletoe Extracts from Various Host Trees

Cell Lines	Conc. to Inhibit Tumor Cell Growth by 50% (IC ₅₀) (ng/mL)					
	Quercus	Castanea	Chaenomeles	Prunus	Ailanthus	Pyrus
YAC-1	2100	400	1600	90	1800	1600
RAW	2500	1600	1700	590	2200	2600
Molt-4	1400	500	1000	140	1000	1000

EXAMPLE 23: Immunological Stimulation by KMHBP and Lectin Fraction Combinations

As revealed in Example 4, the effective concentration at which the lectin fraction KML-C can induce cytokines such as TNF- α , IL-1 and IL-6 ranges from 5 to 100 ng/ml.

For the induction of IFN- γ , KMHBP has an effective concentration range from 1 to 5 $\mu\text{g/ml}$. Based on these results, 2 μg of KMHBP and 20 ng of KML-C were mixed in 1 ml of PBS (the resulting fraction is, hereinafter, referred to as "KM") and KM was examined for the cytokine induction ability from lymphocytes of the spleen of normal mice in the same manner as in Example 4. The result is given in Table 12, below. The KM fraction was found to effectively induce all of the cytokines tested, TNF- α , IL-1, IFN- γ and IL-6.

TABLE 12

Activity of KM Fraction to Induce Cytokines

Samples	Cytokines				
	IL-1	TNF- α	IFN- γ	IL-6	Cytotoxicity IC ₅₀ :ng/mL
KML-C (20ng)	172 \pm 25	311 \pm 26	0	313 \pm 15	2.5 \pm 0.3
KM-AS (2 μg)	169 \pm 12	220 \pm 31	162 \pm 20	220 \pm 22	30 \pm 2.5
KMHBP-100 (2 μg)	0	25 \pm 4	356 \pm 42	156 \pm 22	1560 \pm 62
KM (2 μg)	195 \pm 21	256 \pm 31	292 \pm 21	286 \pm 35	225 \pm 13

This data shows that the KM fraction is endowed with the KMHBP's ability to induce INF- γ , which is not induced by lectins, in addition to being similar in induction activity to KM-110 or KM-AS with a great decrease in direct cytotoxicity on normal cells. KM showed 7 times as low

direct cytotoxicity on normal cells as KMHBP-100. Therefore, the KM fraction is improved not only in cytokine induction activity, but also in safety to normal cells.

5 EXAMPLE 24: *in vivo* Toxicity of KM Fraction

10 The KM fraction was measured for *in vivo* acute toxicity in the same manner as in Example 6 and the result is given in Table 13, below. In this experiment, KM-AS, a protein fraction of KM-110, was used as a control.

15 As seen in Table 13, KM-AS has an LD₅₀ of 10-15 μ g/mouse while 75 μ g/mouse was given to the LD₅₀ of the KM fraction. In the group which was administered with KM at 100 μ g/mouse, no mice were found to die a sudden death within 6 hours. The mouse members all suffered from piloerection and adynamia due to the pyrexia caused by the induction of excessive inflammatory cytokines and were finally put to death within 72 hours. The mice survived in the group which was administered with LD₅₀ of KM, that is, 20 75 μ g/?kg, and were observed to suffer from piloerection and adynamia until the fifth day after the administration and then, revived to the normal state. In contrast to the KM fraction, the KM-AS fraction caused mice to undergo adynamia immediately after the injection at a dose of 15 25 μ g/kg? and died within 24 hours after the injection. All mice of the group injected with KM-AS at a dose of 10

0927165-072700

$\mu\text{g/kg}$? survived. In them, a slight adynamia and piloerection was observed for 1-3 days after the injection, and then, they revived. Thus, KM-AS, a protein fraction of KM-110, contained a material or materials lethal to mice.

5 The KM fraction, composed of KMHBP, separated through a heparin column, and KML-C, did not cause a sudden death in mice, so that the lethal material(s) was removed by the separation through the heparin column.

10

TABLE 13

Mortality Upon Intravenous Injection of KM Fraction

15

Samples	Dose	Days/Viability (%)							Results (%)
		1	2	3	4	5	6	7	
KM-AS	15 μg	0	-	-	-	-	-	-	0
KM	10 μg	100	100	100	100	100	100	100	100
	100 μg	40	20	0	-	-	-	-	0
	75 μg	80	40	40	40	40	40	40	40
	50 μg	100	100	100	100	100	100	100	100
	25 μg	100	100	100	100	100	100	100	100

20

EXAMPLE 25: Repressive Activity of KM Fraction Against Tumor Metastasis

The KM fraction was examined for the repressive activity against tumor metastasis. Preventive effects of

KM fractions on cancer cells were made as described in Example 7 while KM-110 (100 μ g), KM-AS (2 μ g) and KML-C were used as positive controls. As given in Table 14, below, no differences existed between the positive control

5 group and KM, indicating that the KM fraction maintained the activity of KM-110 as it was.

TABLE 14

Repressive Activity of KM Fraction Against Tumor

10 Metastasis

Samples	Dose	Lung Cancer No.±SD(% Inhibition)	Ranges
Control	-	186±25 (-)	156-210
15 KM-100	100 μ g	25±6 (86.6)	19-32
KM-AS	2 μ g	22±8 (88.2)	15-30
KML-C	50ng	30±6 (83.9)	24-37
KM	5 μ g	20±5 (89.2)	15-25
KM	1 μ	22±6 (88.2)	16-28
20 KM	200ng	40±7 (78.5)	32-49

Taken together, the data obtained above demonstrate that the Korean mistletoe extract KM-110 and its purified

25 fractions, such as, the KM-110-derived protein fraction KM-AS, the lectin fraction KML-C, the two lectins KML-IIU and KML-IIL, the protein KMHBP, separated through heparin

column from C-free AS which is a fraction of KM-AS free of
KML-C, and the mixed fraction KM containing the KMHBP and
the KML-C, each has the functions of stimulating humoral
and cell-mediated immune systems to enhance the totality of
5 host immune mechanisms as well as of activating macrophages
and natural killer cells, both taking direct and indirect
part in controlling tumor cells, to improve the antitumoral
activity of hosts. Therefore, the present invention finds
numerous applications in the biological, medicinal,
10 pharmacological and immunological industries.

The present invention has been described in an
illustrative manner, and it is to be understood that the
terminology used is intended to be in the nature of
description rather than of limitation. Many modifications
and variations of the present invention are possible in
15 light of the above teachings. Therefore, it is to be
understood that within the scope of the appended claims,
the invention may be practiced otherwise than as
specifically described.

20

25

SEQUENCE LISTING

<110> KIM, Jong-Bae

<120> CRUDE EXTRACT FROM *Viscum album coloratum*, AND PROTEINS
AND LECTINS ISOLATED THEREFROM

<130> Korean Mistletoe Lectin

<140> 99-30638

<141> 1999-07-27

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 762

<212> DNA

<213> *Viscum album coloratum*

<400> 1

```
tacgagaggc taagactcag agttacgcat caaaccacgg gcgacgaata ttccgggttc 60
atcacgcttc tccgagatta tgtctcaagc ggaagctttt ccaatgagat accactcttg 120
cgtcagtcta cgatccccgt ctccgatgcg caaagatttg tgttggtgga actcaccaat 180
cagggggggag actcgatcac ggccgccatc gacgttacta acctgtacgt ggtgggttac 240
caagcaggcg accaatccta cttttgccc gacgcaccag acggcgcgga aaggcatctc 300
ttcaccggca ccaccagatc ctccctcca ttcaccggaa gctacacaga tctggagcga 360
ttcgccggtc atagggacca galccctctg ggtagagagg aactcattca atccgtctcg 420
gcccttcgtt ttccgggcag caacactcgt gcccaagctc gtctctttat catctctatt 480
cagatgatct ccgaggccgc cagattcaat cccatcttat ggagggtctg ccaatacatt 540
agcagtgggg ggtcatttct gccagacacg tacattctcc agctggagac gatttggggg 600
caacaatcca cgcaagtca gactcgacg gatggcggtt ttaataaccc aattcggttg 660
actatatcca ctggtgtctt cgtgacgttg agcaatgttc gcgacgtgat cgccagctta 720
gcgatcatgt tgtttgatg cgaggaccgg ccattctct ct 762
```

<210> 2

<211> 254

<212> PRT

<213> *Viscum album coloratum*

<400> 2

```
Tyr Glu Arg Leu Arg Leu Arg Val Thr His Gln Thr Thr Gly Asp Glu
1      5      10      15
```

002220" 59T 22560

5 Tyr Phe Arg Phe Ile Thr Leu Leu Arg Asp Tyr Val Ser Ser Gly Ser
20 25 30

Phe Ser Asn Glu Ile Pro Leu Leu Arg Gln Ser Thr Ile Pro Val Ser
35 40 45

10 Asp Ala Gln Arg Phe Val Leu Val Glu Leu Thr Asn Gln Gly Gly Asp
50 55 60

15 Ser Ile Thr Ala Ala Ile Asp Val Thr Asn Leu Tyr Val Val Ala Tyr
65 70 75 80

Gln Ala Gly Asp Gln Ser Tyr Phe Leu Arg Asp Ala Pro Asp Gly Ala
85 90 95

20 Glu Arg His Leu Phe Thr Gly Thr Thr Arg Ser Ser Leu Pro Phe Thr
100 105 110

25 Gly Ser Tyr Thr Asp Leu Glu Arg Phe Ala Gly His Arg Asp Gln Ile
115 120 125

Pro Leu Gly Arg Glu Glu Leu Ile Gln Ser Val Ser Ala Leu Arg Phe
130 135 140

30 Pro Gly Ser Asn Thr Arg Ala Gln Ala Arg Ser Phe Ile Ile Leu Ile
145 150 155 160

Gln Met Ile Ser Glu Ala Ala Arg Phe Asn Pro Ile Leu Trp Arg Ala
165 170 175

35 Arg Gln Tyr Ile Ser Ser Gly Gly Ser Phe Leu Pro Asp Thr Tyr Ile
180 185 190

40 Leu Gln Leu Glu Thr Ser Trp Gly Gln Gln Ser Thr Gln Val Gln His
195 200 205

Ser Thr Asp Gly Val Phe Asn Asn Pro Ile Arg Leu Thr Ile Ser Thr
210 215 220

45 Gly Val Phe Val Thr Leu Ser Asn Val Arg Asp Val Ile Ala Ser Leu
225 230 235 240

50 Ala Ile Met Leu Phe Val Cys Glu Asp Arg Pro Ser Ser Ser
245 250

<210> 3
 <211> 762
 <212> DNA
 5 <213> *Viscum album coloratum*

 <400> 3
 tacgagaggc taagactcag agttacgcat caaaccacgg gcgaccaata ttcaagttc 60
 atcacgcttc tccgagatca tgttcaagc ggaagcttgt ccaatcaaat accactcttg 120
 10 cggcagtccta ctgtccccgt ctcgatacag cagagatttg tgttggtgga actcagcaat 180
 caggggggag actcgatcac ggccgccatc gacgttacca atctgtacgt ggtggcttac 240
 caagcaggca accaatccta cttttgcgc gacgcacctc gcggcgcgga aacgtatctc 300
 ttcaccggca ccaccgcatc ctctctccca ttcaacggaa gctaccctga tctggagcga 360
 15 tacgccggac atagggacca gatccctctc ggtatagacc aactcatca atcgtctctg 420
 gcccttcgtt ttccgggcag caacactcgt gcccaagctc gttcctttat catctctatt 480
 cagatgatct ccgaggccgc cagattcaat cccatcttat ggagggtctg ccaatacatt 540
 agcagtgggg ggtcatttct gccagacacg tacattctcc agctggagac gagttggggg 600
 caacaatcca cgcaagtcca gactcgacg gatggcggtt ttaataaccc aattcggttg 660
 20 actatatcca ctggtgtctt cgtgacgttg agcaatgttc gcgacgtgat cgccagcyta 720
 gcgatcatgt tgttgtatg cgaggaccgg ccatctctct ct 762

 <210> 4
 25 <211> 254
 <212> PRT
 <213> *Viscum album coloratum*

 <400> 4
 Tyr Glu Arg Leu Arg Leu Arg Val Thr His Gln Thr Thr Gly Asp Gln
 1 5 10 15

 Tyr Phe Lys Phe Ile Thr Leu Leu Arg Asp His Val Ser Ser Gly Ser
 20 25 30

 Leu Ser Asn Gln Ile Pro Leu Leu Arg Gln Ser Thr Val Pro Val Ser
 35 40 45

 40 Asp Thr Gln Arg Phe Val Leu Val Glu Leu Ser Asn Gln Gly Gly Asp
 50 55 60

 Ser Ile Thr Ala Ala Ile Asp Val Thr Asn Leu Tyr Val Val Ala Tyr
 65 70 75 80

 Gln Ala Gly Asn Gln Ser Tyr Phe Leu Arg Asp Ala Pro Arg Gly Ala
 85 90 95

 50 Glu Thr Tyr Leu Phe Thr Gly Thr Thr Arg Ser Ser Leu Pro Phe Asn

```

      100      105      110
5      Gly Ser Tyr Pro Asp Leu Glu Arg Tyr Ala Gly His Arg Asp Gln Ile
      115      120      125

      Pro Leu Gly Ile Asp Gln Leu Ile Gln Ser Val Ser Ala Leu Arg Phe
      130      135      140
10

      Pro Gly Ser Asn Thr Arg Ala Gln Ala Arg Ser Phe Ile Ile Leu Ile
      145      150      155      160

      Gln Met Ile Ser Glu Ala Ala Arg Phe Asn Pro Ile Leu Trp Arg Ala
      165      170      175
15

      Arg Gln Tyr Ile Ser Ser Gly Gly Ser Phe Leu Pro Asp Thr Tyr Ile
      180      185      190
20

      Leu Gln Leu Glu Thr Ser Trp Gly Gln Gln Ser Thr Gln Val Gln His
      195      200      205

      Ser Thr Asp Gly Val Phe Asn Asn Pro Ile Arg Leu Thr Ile Ser Thr
      210      215      220
25

      Gly Val Phe Val Thr Leu Ser Asn Val Arg Asp Val Ile Ala Ser Xaa
      225      230      235      240

      Ala Ile Met Leu Phe Val Cys Glu Asp Arg Pro Ser Ser Ser
      245      250
30

<210> 5
<211> 768
<212> DNA
<213> Viscum album coloratum
35

40
<400> 5
tacgagaggc taagactcag agttacgcat caaaccacgg gcgacgaata ttccgggttc 60
atcaagcttc tccgagactc tgtctcaagc ggaagctttt ccaatgacat accgctcctg 120
cctccgtcaa tcccggtctc ctctgcgcag agatttgtgt tgggtggaact cacaaatcag 180
ttgggaaagt gggaagactc gatcacggcc gccatcgacg ttaccaatct gtacgtggtg 240
gtttaccaag caggcgacca atcctacttt ttgcgcgacg caccagacgg cgcggaagg 300
catctcttca ccggcaccac cagatcctct ctctcttca acggaagcta cgctgatctg 360
gagcggtagc ccggacatag ggaccggatc cctctgggta gagagccact catacgatcc 420
gtctcggcgc ttgattatcc cggcggcagc acgcgcgcc aagccagttc cattattatc 480
gtattcaga tgatctccga ggcggccaga ttaatccca tctatggag ggctcgccaa 540
tacaltaaca gtgggggtgc atatctcca gacgtgtaca tgctggagct ggaggcgagt 600

```

tggggccaac aatcgaccca agtcacagcag togaccgatg gcgtttttaa taacccaatt 660
 cgggttgaggta tatccaccgg caacttcgtg tgggtgagca atgttcgcga cgtgatcgcc 720
 agcttgggga tcatggtgtt tgcatagcagg gaccggtcat cttccct 768

5

<210> 6

<211> 256

10

<212> PRT

<213> Viscum album coloratum

<400> 6

15

Tyr Glu Arg Leu Arg Leu Arg Val Thr His Gln Thr Thr Gly Asp Glu

1 5 10 15

Tyr Phe Arg Phe Ile Lys Leu Leu Arg Asp Ser Val Ser Ser Gly Ser

20 25 30

20

Phe Ser Asn Asp Ile Pro Leu Leu Pro Pro Ser Ile Pro Val Ser Ser

35 40 45

25

Ala Gln Arg Phe Val Leu Val Glu Leu Thr Asn Gln Leu Gly Lys Trp

50 55 60

Glu Asp Ser Ile Thr Ala Ala Ile Asp Val Thr Asn Leu Tyr Val Val

65 70 75 80

30

Ala Tyr Gln Ala Gly Asp Gln Ser Tyr Phe Leu Arg Asp Ala Pro Asp

85 90 95

Gly Ala Glu Arg His Leu Phe Thr Gly Thr Thr Arg Ser Ser Leu Pro

100 105 110

35

Phe Asn Gly Ser Tyr Ala Asp Leu Glu Arg Tyr Ala Gly His Arg Asp

115 120 125

40

Arg Ile Pro Leu Gly Arg Glu Pro Leu Ile Arg Ser Val Ser Ala Leu

130 135 140

Asp Tyr Pro Gly Gly Ser Thr Arg Ala Gln Ala Ser Ser Ile Ile Ile

145 150 155 160

45

Val Ile Gln Met Ile Ser Glu Ala Ala Arg Phe Asn Pro Ile Leu Trp

165 170 175

50

Arg Ala Arg Gln Tyr Ile Asn Ser Gly Val Ser Tyr Leu Pro Asp Val

180 185 190

002240.597255

Tyr Met Leu Glu Leu Glu Ala Ser Trp Gly Gln Gln Ser Thr Gln Val
195 200 205

5 Gln Gln Ser Thr Asp Gly Val Phe Asn Asn Pro Ile Arg Leu Gly Ile
210 215 220

10 Ser Thr Gly Asn Phe Val Trp Leu Ser Asn Val Arg Asp Val Ile Ala
225 230 235 240

15 Ser Leu Gly Ile Met Val Phe Val Cys Arg Asp Arg Ser Ser Ser Pro
245 250 255

20 <210> 7
<211> 797
<212> DNA
<213> Viscum album coloratum

25 <400> 7
acgatgtaac ctgcactact tccgaaccta cggtagcggtt tgtgggtcga aatggcctgt 60
gtctcgacgt ccagaggggc gattaccacg atggaagtcg gatacagttg tggccctgca 120
agtccaactc cgtacagaat cagctgtgga cgtacagaag ggatggaacc atctgactta 180
atggaagggtg cttgacgacc tatgggtata ctgcgggcag ctatataatg atctacgact 240
30 gtaatagagg ggggtgggac ctactactt ggcagataag gggcaatgga atcatcctta 300
atccaagatc catgatgggtg atcgaacac catccgggag ccgcggaacc cgtggcacta 360
ctttactct gcaaactg ggttactcat taggacaggg ctggcttccc agcaatgata 420
ccgctcctcg cgaggtaacc atatatggtt tccgcgatca ttgcatggaa actagtggag 480
35 ggaaagtgtg ggttgggact tgtgtgagtg gcaagcagaa ccaaagatgg gctttgtacg 540
gggatgggtc cattcgcccg aaaccttacc aagaccaatg cctcacctct caggagact 600
ccgttagatc cgtaatcaat ttatttagct gcaccgctgg atcgccaagg caacgatggg 660
tattaccaa taaaggggcc atttgaatt taaagaatag gttggccatg gatgtggcgg 720
aatcaaatcc aagcctccgc cgaataatca tctttcagt cactggaaat ccaaatcaaa 780
40 tgtgcttcc cgtgcca 797

45 <210> 8
<211> 266
<212> PRT
<213> Viscum album coloratum

50 <400> 8
Asp Asp Val Thr Cys Thr Thr Ser Glu Pro Thr Val Arg Phe Val Gly
1 5 10 15

5 Arg Asn Gly Leu Cys Leu Asp Val Pro Glu Gly Asp Tyr His Asp Gly
 20 25 30
 Ser Arg Ile Gln Leu Trp Pro Cys Lys Ser Asn Ser Asp Gln Asn Gln
 35 40 45
 10 Leu Trp Thr Ile Arg Arg Asp Gly Thr Ile Arg Ser Asn Gly Arg Cys
 50 55 60
 Leu Thr Thr Tyr Gly Tyr Thr Ala Gly Ser Tyr Ile Met Ile Tyr Asp
 65 70 75 80
 15 Cys Asn Arg Gly Gly Trp Asp Leu Thr Thr Trp Gln Ile Arg Gly Asn
 85 90 95
 20 Gly Ile Ile Leu Asn Pro Arg Ser Met Met Val Ile Gly Thr Pro Ser
 100 105 110
 Gly Ser Arg Gly Thr Arg Gly Thr Thr Phe Thr Leu Gln Thr Leu Gly
 115 120 125
 25 Tyr Ser Leu Gly Gln Gly Trp Leu Ala Ser Asn Asp Thr Ala Pro Arg
 130 135 140
 30 Glu Val Thr Ile Tyr Gly Phe Arg Asp His Cys Met Glu Thr Ser Gly
 145 150 155 160
 Gly Lys Val Trp Val Gly Thr Cys Val Ser Gly Lys Gln Asn Gln Arg
 165 170 175
 35 Trp Ala Leu Tyr Gly Asp Gly Ser Ile Arg Pro Lys Pro Tyr Gln Asp
 180 185 190
 40 Gln Cys Leu Thr Ser Gln Gly Asp Ser Val Arg Ser Val Ile Asn Leu
 195 200 205
 Phe Ser Cys Thr Ala Gly Ser Pro Arg Gln Arg Trp Val Phe Thr Asn
 210 215 220
 45 Lys Gly Ala Ile Leu Asn Leu Lys Asn Arg Leu Ala Met Asp Val Ala
 225 230 235 240
 50 Glu Ser Asn Pro Ser Leu Arg Arg Ile Ile Ile Phe Ser Val Thr Gly
 245 250 255
 Asn Pro Asn Gln Met Trp Leu Pro Val Pro
 70

002220"5972960

096245-072700

260

265

5

<210> 9

<211> 789

<212> DNA

10

<213> Viscum album coloratum

<400> 9

15

gacgatggta cctgcactgc ttccgaacct acggtgcgga ttgtgggtct aaatggcctg 60
tgcgtcgacg tccgaaatgg aaaattccac gatggaaatc cgatacagtt gtggccctgc 120
aagccaaca ccgataggaa tcagctgtgg acgatcagaa gggatggaac cattcgatct 180
aatagcaagt gcttgaccac ctatggctat cgtgatggca tgtatgtaat gatctacaac 240
tgtaatcagg ccgtgcggga ggccactatt tggcaaatat gggaaaatgg aaccatcgtt 300
aatccaagat ccagtctggt actgggagca gcatctggaa acagccgcac taggcttact 360
gtgcaaacac aggccttact gtgggacag ggctggcttg ccagcaatga taccgccctt 420
cgcgaggtaa ccatatacgg attccgtgac ctttgcattg aagctaattg atcgagtgtg 480
tgggtggaga ctgtgtgag taacaagcag aacaaaaaat gggctttgta cggggatggt 540
tctatacgcc ccaaacaaaa ccgaaaccaa tgctcactt gccagaaaga ctccgtttca 600
accgtaatca atattgttag ctgcagcgca ggatcgtctg ggcagcgatg ggtgtttacc 660
aataaaggga ccattttgaa tttaaagaat gggttggta tggatgtggc gcaatcaaat 720
ccaagcctcc gccgaataat catctacca gccaccggaa agcctaata aatgtggctt 780
cccgtgccca 789

30

<210> 10

<211> 263

<212> PRT

<213> Viscum album coloratum

35

<400> 10

Asp Asp Gly Thr Cys Thr Ala Ser Glu Pro Thr Val Arg Ile Val Gly
1 5 10 15

40

Leu Asn Gly Leu Cys Val Asp Val Arg Asn Gly Lys Phe His Asp Gly
20 25 30

Asn Pro Ile Gln Leu Trp Pro Cys Lys Ser Asn Thr Asp Arg Asn Gln
35 40 45

45

Leu Trp Thr Ile Arg Arg Asp Gly Thr Ile Arg Ser Asn Ser Lys Cys
50 55 60

50

Leu Thr Thr Tyr Gly Tyr Arg Asp Gly Met Tyr Val Met Ile Tyr Asn
65 70 75 80

5 Cys Asn Thr Ala Val Arg Glu Ala Thr Ile Trp Gln Ile Trp Glu Asn
85 90 95

Gly Thr Ile Val Asn Pro Arg Ser Ser Leu Val Leu Gly Ala Ala Ser
100 105 110

10 Gly Asn Ser Arg Thr Arg Leu Thr Val Gln Thr Gln Ala Tyr Ser Leu
115 120 125

Gly Gln Gly Trp Leu Ala Ser Asn Asp Thr Ala Pro Arg Glu Val Thr
15 130 135 140

Ile Tyr Gly Phe Arg Asp Leu Cys Met Glu Ala Asn Gly Ser Ser Val
145 150 155 160

20 Trp Val Glu Thr Cys Val Ser Asn Lys Gln Asn Gln Lys Trp Ala Leu
165 170 175

Tyr Gly Asp Gly Ser Ile Arg Pro Lys Gln Asn Arg Asn Gln Cys Leu
25 180 185 190

Thr Cys Gln Lys Asp Ser Val Ser Thr Val Ile Asn Ile Val Ser Cys
195 200 205

30 Ser Ala Gly Ser Ser Gly Gln Arg Trp Val Phe Thr Asn Lys Gly Thr
210 215 220

Ile Leu Asn Leu Lys Asn Gly Leu Val Met Asp Val Ala Gln Ser Asn
35 225 230 235 240

Pro Ser Leu Arg Arg Ile Ile Ile Tyr Pro Ala Thr Gly Lys Pro Asn
245 250 255

40 Gln Met Trp Leu Pro Val Pro
260

<210> 11

45 <211> 789

<212> DNA

<213> Viscum album coloratum

<400> 11

50

gacgatggaa cctgcactcc ttccgaacct acggtgtgga ttgtgggtct aaatggcctg 60
tgcgtcgacg tccgacatgg aaaattccac gatggaaatc cgatacagtt gtggccctgc 120
aagtccaaca ccgataggaa tcagctgtgg acgatcagaa gggatggaac cattcgatct 180
72

09027165-072700

5 aatagcaagt gcttgaccac ctatggctat cgtgatggca tgtatgtcat gatctacaac 240
tgtaatacgg ccgtgcggga ggccactatt tggcaaatat gggaaaatgg aaccatcggt 300
aatccaaaat ccagtctggt actgggagca gcatctggaa gcagccgcac tacgcttact 360
gtgcaaacac aggcttactc gttgggacag ggctggcttg ccagccatga tacagcccct 420
cgcgaggtaa ccatacagc ttccgtgac ctttgcattg aagctaattg atcgagtgtg 480
tkggtggaga cttgtgtgag tcacaagcag aacaaaaaat gggctttgta cggggatggt 540
10 tctatacgcc ccaaacaaaa ccgaaaccaa tgcctcacct gccagaaaga ctccgtttca 600
accgtaatca atattgtag ctgcagcgca ggatcgtctg ggcagcgatg ggtgtttacc 660
aataaaggga ccattttgaa ttaaagaat gggttgggcc tggatgtggc gcaatcaaat 720
ccaagcctcc gccgaataat catctacca gccaccggaa agcctaata aatgtggcct 780
15 cccgtgcca 789

20 <210> 12
<211> 263
<212> PRT
<213> Viscum album coloratum

25 <400> 12
Asp Asp Gly Thr Cys Thr Pro Ser Glu Pro Thr Val Trp Ile Val Gly
1 5 10 15
Leu Asn Gly Leu Cys Val Asp Val Arg His Gly Lys Phe His Asp Gly
20 25 30

30 Asn Pro Ile Gln Leu Trp Pro Cys Lys Ser Asn Thr Asp Arg Asn Gln
35 40 45

35 Leu Trp Thr Ile Arg Arg Asp Gly Thr Ile Arg Ser Asn Ser Lys Cys
50 55 60

Leu Thr Thr Tyr Gly Tyr Arg Asp Gly Met Tyr Val Met Ile Tyr Asn
65 70 75 80

40 Cys Asn Thr Ala Val Arg Glu Ala Thr Ile Trp Gln Ile Trp Glu Asn
85 90 95

45 Gly Thr Ile Val Asn Pro Lys Ser Ser Leu Val Leu Gly Ala Ala Ser
100 105 110

Gly Ser Ser Arg Thr Thr Leu Thr Val Gln Thr Gln Ala Tyr Ser Leu
115 120 125

50 Gly Gln Gly Trp Leu Ala Ser His Asp Thr Ala Pro Arg Glu Val Thr
130 135 140

002220" 09T 0000

5 Ile Tyr Gly Phe Arg Asp Leu Cys Met Glu Ala Asn Gly Ser Ser Val
145 150 155 160

Xaa Val Glu Thr Cys Val Ser His Lys Gln Asn Gln Lys Trp Ala Leu
165 170 175

10 Tyr Gly Asp Gly Ser Ile Arg Pro Lys Gln Asn Arg Asn Gln Cys Leu
180 185 190

Thr Cys Gln Lys Asp Ser Val Ser Thr Val Ile Asn Ile Val Ser Cys
195 200 205

15 Ser Ala Gly Ser Ser Gly Gln Arg Trp Val Phe Thr Asn Lys Gly Thr
210 215 220

20 Ile Leu Asn Leu Lys Asn Gly Leu Val Leu Asp Val Ala Gln Ser Asn
225 230 235 240

Pro Ser Leu Arg Arg Ile Ile Ile Tyr Pro Ala Thr Gly Lys Pro Asn
245 250 255

25 Gln Met Trp Leu Pro Val Pro
260

30

35

40

45

50

<210> 13

<211>

<212> DNA

5

<213> Viscum album coloratum

<400> 13

10

GCC AGA TTC AAT CCC ATC NTG TGG AGG CTT CGC CGG CAA ATT AAC
 A R F V P I X W R L R R Q I N
 AGT CCG GAC TCN TCT CCA CCA AAC ATG TAC ATC CTC GAG CTG CAG
 S G E S S P P N M Y M L E L E
 ACG AGT TGG GGT CCA CAA TCC ACC CAA CTC CAG CAG TCC AAC GAT
 T S W G R Q S T Q V Q Q S K D
 15 GCC ATT TTT AAT ACC CAA ATA AGA TTG CAG ATT TCC GCC GGT AAC
 G I F N T Q I R L Q I S A G N
 TTT GTG ACG NTG AGC AAT GTT CGC GAC GTG ATC TCC AGC TTG GCG
 F V T X S N V R D V I S S L A
 20 ATC ATG TTG TTC GAA TCC AGT GGT CGG CCA TTC TCC TCT CTC GAC
 I M L F E C S G R P F S S L D
 CAC CCT TCG CCG CTC CTC CTA AGG TCC GTC GTG GAT GCG GCC AAC
 H P S P L L L R S V V D A A N
 25 CAT GTC ACC TCC ACT NTT TCC CAA CCC ACC GTG CGC ATC GTA
 D V T C T X S E P T V R I V

30

<210> 14

<211>

<212> PRT

<213> Viscum album coloratum

35

<400> 14

40

GCC AGA TTC AAT CCC ATC NTG TGG AGG CTT CGC CGG CAA ATT AAC
 A R F N P I X W R L R R Q I N
 AGT GGG GAG TCN TCT CCA CCA AAC ATG TAC ATG CTC GAG CTG GAG
 S G E S S P P N M Y M L E L E
 ACG AGT TGG GGT CCA CAA TCC ACC CAA GTC CAG CAG TCC AAG GAT
 T S W G R Q S T Q V Q Q S K D
 45 GGC ATT TTT AAT ACC CAA ATA AGA TTG CAG ATT TCC GCC GGT AAC
 G I F N T Q I R L Q I S A G N
 TTT GTG ACG NTG AGC AAT GTT CGC GAC GTG ATC TCC AGC TTG GCG
 F V T X S N V R D V I S S L A
 ATC ATG TTG TTC GAA TCC AGT GGT CGG CCA TTC TCC TCT CTC GAC
 I M L F E C S G R P F S S L D
 50 CAC CCT TCG CCG CTC CTC CTA AGG TCC GTC GTG GAT GCG GCC AAC
 H P S P L L L R S V V D A A N
 GAT GTC ACC TCC ACT NTT TCC CAA CCC ACC GTG CGC ATC GTA
 D V T C T X S E P T V R I V

<210> 15

<211>

<212> DNA

<213> Viscum album coloratum

<400> 15

5

10

15

20

25

<210> 16

<211>

<212> PRT. A S E P T V R I V

<213> Viscum album coloratum

30

35

40

45

50

TAC ACA GAT CTG GAG CGA TAC GCC GGT CAT AGG GAC CAG ATC CCT
Y T D L E R Y A G H R D Q I P
CTG GGT ATA GAG GAA CTC ATT CAA TCC GTC TCG GCG CTT CGT TAT
L G I E E L I Q S V S A L R Y
CCA GGC GGC AGC ACC CGG GCC CAA GCT CGT TCC CTT ATA ATC CTC
P G G S T R A Q A R S L I I L
ATT CAG ATG ATC TCC GAG GCC GCG AGA TTC AAT CCC ATC TTT TGG
I Q M I S E A A R F N P I F W
AGG GCT CGC CAA TAC ATT AAC AGC GCG GAG TCA TTT CTT CCC GAC
R A R Q Y I N S G E S F L P D
ATG TAC ATG CTC GAG CTG GAG ACT AGT TGG GCG CAA CAA TCC ACG
M Y M L E L E T S W G Q Q S T
CAA GTC CAG CAG TCT ACG GAT GGC GTT TTT AAT AAC CCA TTT CGG
Q V Q Q S T D G V F N N P F R
TTG GGT ATA TCC ACC CGT AAC TTC GTG ACG TTG AGC AAT GTT CGC
L G I S T G N F V T L S N V R
GAC GTG ATC GCC AGC TTA CGC ATC ATG TTG TTT GTA TGT AGG GAC
D V I A S L A I M L F V C R D
CGA CCA TCT TCC TCC GAC GTG CGC TAT TGG CCG CTG GTC ATA CGA
R P S S S D V R Y W P L V I R
CCC GTC TTG GAA AAT AGC GGC GCC GTC GAC GAT GTT ACC TGC ACT
P V L E N S G A V D D V T C T
GCT TCC GAA CCC ACC GTG CGC ATC GTA
TAC ACA GAT CTG GAG CGA TAC GCC GGT CAT AGG GAC CAG ATC CCT
Y T D L E R Y A G H R D Q I P
CTG GGT ATA GAG GAA CTC ATT CAA TCC GTC TCG GCG CTT CGT TAT
L G I E E L I Q S V S A L R Y
CCA GGC GGC AGC ACC CGG GCC CAA GCT CGT TCC CTT ATA ATC CTC
P G G S T R A Q A R S L I I L
ATT CAG ATG ATC TCC GAG GCC GCG AGA TTC AAT CCC ATC TTT TGG
I Q M I S E A A R F N P I F W
AGG GCT CGC CAA TAC ATT AAC AGC GCG GAG TCA TTT CTT CCC GAC
R A R Q Y I N S G E S F L P D
ATG TAC ATG CTC GAG CTG GAG ACT AGT TGG GCG CAA CAA TCC ACG
M Y M L E L E T S W G Q Q S T
CAA GTC CAG CAG TCT ACG GAT GGC GTT TTT AAT AAC CCA TTT CGG
Q V Q Q S T D G V F N N P F R
TTG GGT ATA TCC ACC CGT AAC TTC GTG ACG TTG AGC AAT GTT CGC
L G I S T G N F V T L S N V R
GAC GTG ATC GCC AGC TTA CGC ATC ATG TTG TTT GTA TGT AGG GAC
D V I A S L A I M L F V C R D
CGA CCA TCT TCC TCC GAC GTG CGC TAT TGG CCG CTG GTC ATA CGA
R P S S S D V R Y W P L V I R
CCC GTC TTG GAA AAT AGC GGC GCC GTC GAC GAT GTT ACC TGC ACT
P V L E N S G A V D D V T C T
GCT TCC GAA CCC ACC GTG CGC ATC GTA
A S E P T V R I 76

002220.09742960

What is claimed is:

1. A nucleotide sequence of an isoform of an A-chain gene involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO. 1.

5

2. An amino acid sequence deduced from the sequence of claim 1, involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO 2.

10

3. A nucleotide sequence of an isoform of an A-chain gene involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO. 3.

15

4. An amino acid sequence deduced from the sequence of claim 3, involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO 4.

20

5. A nucleotide sequence of an isoform of an A-chain gene involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO. 5.

25

6. An amino acid sequence deduced from the sequence of claim 5, involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO. 6.

7. A nucleotide sequence of an isoform of a B-chain

gene involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO. 7.

8. An amino acid sequence deduced from the sequence of claim 7, involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO. 8.

9. A nucleotide sequence of an isoform of a B-chain gene involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO. 9.

10. An amino acid sequence deduced from the sequence of claim 9, involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO. 10.

11. A nucleotide sequence of an isoform of a B-chain gene involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO. 11.

12. An amino acid sequence deduced from the sequence of claim 11, involved in biosynthesizing lectins isolated from Korean mistletoe, comprising SEQ ID NO. 12.

13. A lectin isolated from Korean mistletoe.

14. The lectin of claim 13, wherein the lectin is

selected from the group consisting of KML-IIU and KML-IIL.

15. The lectin of claim 14, wherein the lectin is KML-IIU.

5

16. The lectin of claim 15, wherein the lectin has a molecular weight of 61.8 kD.

17. The lectin of claim 14, wherein the lectin is KML-IIL.

10

18. The lectin of claim 17, wherein the lectin has a molecular weight of 56.4 kD.

19. A method for preparing a lectin isolated from Korean mistletoe comprising separating a lectin fraction extracted from Korean mistletoe by immuno-affinity column chromatography.

15

20. The method of claim 19, wherein the lectin fraction is KML-C.

20

21. The method of claim 20, wherein the lectin is selected from the group consisting of KML-IIU and KML-IIL.

25

22. The method of claim 21, wherein the immuno-

affinity column is a HiTrip NHS activated affinity column
in which 9H7-D10 antibody is immobilized.

23. A method of enhancing immunity comprising
5 administering to an animal a lectin isolated from Korean
mistletoe.

24. The method of claim 23, wherein the lectin is
selected from the group consisting of KML-IIU OR KML-IIL.
10

25. The method of claim 24, wherein the lectin is
KML-IIU.

26. The method of claim 25, wherein the lectin has
15 a molecular weight of 61.8 kD.

27. The method of claim 24, wherein the lectin is
KML-IIL.

28. The method of claim 27, wherein the lectin has a
20 molecular weight of 56.4 kD.

29. A method of effectuating antitumoral activity,
comprising administering to an animal a lectin isolated
25 from Korean mistletoe.

30. The method of claim 29, wherein the lectin is selected from the group consisting of KML-IIU OR KML-IIL.

5 31. The method of claim 30, wherein the lectin is KML-IIU.

32. The method of claim 31, wherein the lectin has a molecular weight of 61.8 kD.

10 33. The method of claim 30, wherein the lectin is KML-IIL.

34. The method of claim 33, wherein the lectin has a molecular weight of 56.4 kD.

15 35. A gene encoding a lectin isolated from Korean mistletoe, comprising SEQ ID No 13.

36. A protein having SEQ ID NO 14.

20 37. A gene encoding a lectin isolated from Korean mistletoe, comprising SEQ ID NO 15.

38. A protein having SEQ ID NO 16.

25 39. A method of inducing IFN- γ comprising

administering to an animal Korean Mistletoe Heparin Binding Protein (KMHBP).

40. A method of preparing Korean Mistletoe Heparin Binding Protein (KMHBP) protein fraction by binding C-free AS to a heparin column, wherein the C-free AS is a portion of a KM-AS protein free of a KML-C lectin component.

41. A method of enhancing immunity comprising administering to an animal Korean Mistletoe Heparin Binding Protein (KMBHP) protein fraction.

42. A mixture (KM) of KML-C and KMHBP.

43. A method of enhancing immunity and effectuating antitumoral activity comprising use of a mixture (KM) of KML-C and KMHBP.

44. A method of preparing a mixture (KM) of KML-C and KMHBP by combining a lectin component KML-C and a protein fraction KMHBP.

45. A pharmaceutical composition comprising a lectin isolated from Korean mistletoe; and
a pharmaceutically acceptable carrier.

46. The pharmaceutical composition of claim 45,
wherein the lectin is selected from the group consisting of
KM-IIU and KM-IIL.

5 47. A pharmaceutical composition comprising a protein
fraction KMHBP; and
a pharmaceutically acceptable carrier.

10 48. A pharmaceutical composition comprising a mixture
(KM) of KML-C and KMHB; and
a pharmaceutically acceptable carrier.

15

20

25

ABSTRACT

Disclosed is an extract from Korean mistletoe KM-110,
5 which is of immunity enhancement and activity against tumor
metastasis and can be used as an adjuvant material for
vaccines applicable for the induction of humoral and cell-
mediated immunity. Also disclosed are its fractions, a
protein fraction KM-AS, a lectin fraction KML-C, lectin
10 components KML-IIU and KML-IIL, which both are further
purified from lectin fraction KML-C, a protein KMHBP which
is obtained through heparin binding chromatography eluting
with NaCl from a fraction C-free AS which is a portion of
the KM-AS free of KML-C, and a mixture KM of the KMHBP and
15 the KML-C. They are revealed as to their roles in the
humoral and cell-mediated immunity enhancement and
antitumoral activity.

002220-5972960

Figure 1a. TIF:




Figure 1b. jpg:




Figure 2:




Figure 3:




Figure 4:






Figure 5:

A) Induction of IL-1 by KM-110 in various doses



B) Time course of the induction of IL-1 by KM-110



C) Time course of the induction of IL-1 by KM-AS




Figure 6:





Figure 8:



Figure

8:

Figure 7:




Figure 9:




Figure 11:





Figure 10:




Figure 12:




Figure 13:




Figure 14:




Figure 15:





Figure 16:




Figure 17:




Figure 18:




Figure 19:




Figure 20:




Figure 21:




Figure 22:




Figure 23:




Figure 24:




Figure 25:




Figure 26:




Figure 27:




Figure 28:




Figure 29:




Figure 30:




Figure 31:




Figure 32:




Figure 33:





Figure 34:



DECLARATION FOR PATENT APPLICATION

Attorney Docket: 24170
Page 1 of 3

As a below-named inventor(s), I/we hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) is/are as stated below next to my/our name(s).

I/We believe I/we am/are the original inventor, first and sole (if only one name is listed below) or the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed, and for which a patent is sought on the invention entitled:

CRUDE EXTRACT FROM *Viscum album coloratum*, AND PROTEINS AND LECTINS ISOLATED THEREFROM
the specification of which: (check one)

☒ is attached hereto.

☐ was filed on _____, as Serial No. _____, and was amended on _____ (if applicable).

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the patentability of this application as defined by 37 CFR § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Applications:

99-30638
(Application No.)

KOREA
(Country)

27 /July /1999 Priority Claimed
(Day/Month/Year Filed) ☒ ☐
Yes No

(Application No.)

(Country)

/ / ☐ ☐
(Day/Month/Year Filed) Yes No

(Application No.)

(Country)

/ / ☐ ☐
(Day/Month/Year Filed) Yes No

We hereby appoint Gary M. Nath, Reg. No. 26,965; Harold L. Novick, Reg. No. 26,011; Todd L. Juneau, Reg. No. 40,669; Lee C. Heiman, Reg. No. 41,827; Jerald L. Meyer, Reg. No. 41,194; Joshua B. Goldberg, Reg. No. 44,126; David R. Murphy, Reg. No. 22,751; Paul A. Sacher, Reg. No. 43,418; Charles D. Niebylski, Reg. No. 46,116; Deborah H. Yellin, 45,904; Nahied K. Usman, Reg. No. P-47,148; and Roger Hahn, Reg. No. 46,376; as my attorneys to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith.

Direct Telephone Calls to:

Gary M. Nath
(202) 775-8383

Send Correspondence to:
NATH & ASSOCIATES PLLC
Sixth Floor
1030 15th Street, N.W.
Washington, D.C. 20005 U.S.A.

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by 35 U.S.C. § 112, first paragraph, I/we acknowledge the duty to disclose material information as defined in 37 CFR § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(U.S. Application Serial No.)

(U.S. Filing Date)

(Status--patented, pending, abandoned)

(U.S. Application Serial No.)

(U.S. Filing Date)

(Status--patented, pending, abandoned)

DECLARATION FOR PATENT APPLICATION

Attorney Docket: 24170
Page 2 of 3

We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Jongbae KIM

Inventor's Signature _____ Date _____

Residence: 1381, Gokgang-ri, Heunghae-eup, Buk-gu, Pohang-si, Kyongsangbuk-do, REPUBLIC OF KOREACountry of Citizenship: REPUBLIC OF KOREAPost Office Address: same as residenceFull name of second inventor: Seongkyu SONG

Inventor's Signature _____ Date _____

Residence: 1107, Sunwoo Beach, Jangsung-dong, Buk-gu, Pohang-si, Kyongsangbuk-do, REPUBLIC OF KOREACountry of Citizenship: REPUBLIC OF KOREA

Post Office Address: _____

Full name of third inventor: Byungsun SUH

Inventor's Signature _____ Date _____

Residence: 1204, Sunwoo Beach, Jangsung-dong, Buk-gu, Pohang-si, Kyongsangbuk-do, REPUBLIC OF KOREACountry of Citizenship: REPUBLIC OF KOREAPost Office Address: same as residenceFull name of fourth inventor: Kwanee LEE

Inventor's Signature _____ Date _____

Residence: 101-107, Chunggu APT, Woohyun-dong, Buk-gu, Pohang-si, Kyongsangbuk-do, REPUBLIC OF KOREACountry of Citizenship: REPUBLIC OF KOREAPost Office Address: same as residenceFull name of fifth inventor: Myoungsool DOO

Inventor's Signature _____ Date _____

Residence: 109-702, Changpojugong APT, #645, Changpo-dong, Buk-gu, Pohang-si, Kyongsangbuk-do, REPUBLIC OF KOREACountry of Citizenship: REPUBLIC OF KOREAPost Office Address: same as residence

DECLARATION FOR PATENT APPLICATION

Page 3 of 3

Attorney Docket: 24170

We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sixth inventor: Jinhwan KWAK

Inventor's Signature _____ Date _____

Residence: 1008, Hansin APT, #134, Woohyun-dong, Buk-gu, Pohang-si, Kyongsangbuk-do, REPUBLIC OF KOREA

Country of Citizenship: REPUBLIC OF KOREA

Post Office Address: same as residence

Full name of seventh inventor: Byeoungdoo, SONG

Residence: 6-406, Sanho Green APT, Duho-dong, Buk-gu, Pohang-si, Kyongsangbuk-do, REPUBLIC OF KOREA

Inventor's Signature _____ Date _____

Country of Citizenship: REPUBLIC OF KOREA

Post Office Address: same as residence

Full name of eighth inventor: Taekjoon YOON

Inventor's Signature _____ Date _____

Residence: 1043-3, Sungsuk-dong, Ilsan-gu, Goyang-si, Kyonggi-do, REPUBLIC OF KOREA

Country of Citizenship: REPUBLIC OF KOREA

Post Office Address: same as residence

Full name of ninth inventor: Taebong KANG

Inventor's Signature _____ Date _____

Residence: 404, Sangyong Villa 3rd, #133, Joongsung-ri, Heunghae-eup, Buk-gu, Pohang-si, Kyongsangbuk-do, REPUBLIC OF KOREA

Country of Citizenship: REPUBLIC OF KOREA

Post Office Address: same as residence

Full name of tenth inventor: Choonho PARK


Inventor's Signature _____ Date _____

Residence: B-1, Handong University House, #3, Namsong-ri, Heunghae-eup, Buk-gu, Pohang-si, Kyongsangbuk-do, REPUBLIC OF KOREA

Country of Citizenship: REPUBLIC OF KOREA

Post Office Address: same as residence

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ Scanned copy is best available.

Drawings